title: FFA1137_BCM Mixed Dyslipidemia


title: FFA1134_BCM Mixed Dyslipidemia

status: Public on Jan 11 2012

type: genomic

city: houston

first: Ariel

last: Brautbar

address: 1 baylor plaza

country: USA

institute: Baylor College of Medicine

hyb_protocol: RA1 resuspended DNA was loaded onto BeadChips arrays. After overnight incubation at 48¡C, single-base extension and allele-specific staining was performed on a Teflow chamber rack system (Tecan, Maennedorf, Switzerland).

scan_protocol: After allele-specific staining BeadChip arrays were coated with XC4/ethanol , dried for 1 hour and scanned on a BeadArray Reader (Illumina).

data_processing: Image data was analyzed using GenomeStudio v2011.1 with Genotyping module 1.9.4 (Illumina).

label: C-Bio and A-DNP

molecule: genomic DNA

organism: Homo sapiens

source_name: Mixed dyslipidemia_statin alone

label_protocol: 750ng of genomic DNA was whole-genome amplified in an overnight reaction at 37¡C using amplification master mix (WG-AMM) and primer/neutralization mix (WG-MP1). After incubation the amplified DNA was fragmented with fragmentation mix (WG-FRG), precipitated with isopropanol and precipitation mix (PA1) and resuspended in hybridization buffer (RA1).

extract_protocol: Extraction of genomic DNA from peripheral blood

tag: disease state

value: Mixed dyslipidemia

tag: tissue

value: peripheral blood

tag: percent change in apoc3 levels

tag: treatment group

value: statin alone


title: FFA1132_BCM Mixed Dyslipidemia


title: FFA1136_BCM Mixed Dyslipidemia


title: FFA1133_BCM Mixed Dyslipidemia


title: FFA1131_BCM Mixed Dyslipidemia


title: FFA1138_BCM Mixed Dyslipidemia


title: FFA1128_BCM Mixed Dyslipidemia


title: FFA1127_BCM Mixed Dyslipidemia


title: FFA1145_BCM Mixed Dyslipidemia


title: FFA1126_BCM Mixed Dyslipidemia


title: FFA1125_BCM Mixed Dyslipidemia


title: FFA1124_BCM Mixed Dyslipidemia


title: FFA1123_BCM Mixed Dyslipidemia


title: FFA1122_BCM Mixed Dyslipidemia


title: FFA1120_BCM Mixed Dyslipidemia


title: FFA1118_BCM Mixed Dyslipidemia


title: FFA1119_BCM Mixed Dyslipidemia


title: FFA1121_BCM Mixed Dyslipidemia


title: FFA1115_BCM Mixed Dyslipidemia


title: FFA1112_BCM Mixed Dyslipidemia


title: FFA1114_BCM Mixed Dyslipidemia


title: FFA1117_BCM Mixed Dyslipidemia


title: FFA1111_BCM Mixed Dyslipidemia


title: FFA1110_BCM Mixed Dyslipidemia


title: FFA1109_BCM Mixed Dyslipidemia


title: FFA1108_BCM Mixed Dyslipidemia


title: FFA1104_BCM Mixed Dyslipidemia


title: FFA1105_BCM Mixed Dyslipidemia


title: FFA1103_BCM Mixed Dyslipidemia


title: FFA1101_BCM Mixed Dyslipidemia


title: FFA1098_BCM Mixed Dyslipidemia


title: FFA1099_BCM Mixed Dyslipidemia


title: FFA1095_BCM Mixed Dyslipidemia


title: FFA1097_BCM Mixed Dyslipidemia


title: FFA1113_BCM Mixed Dyslipidemia


title: FFA1102_BCM Mixed Dyslipidemia


title: FFA1094_BCM Mixed Dyslipidemia


title: FFA1092_BCM Mixed Dyslipidemia


title: FFA1090_BCM Mixed Dyslipidemia


title: FFA1107_BCM Mixed Dyslipidemia


title: FFA1106_BCM Mixed Dyslipidemia


title: FFA1100_BCM Mixed Dyslipidemia


title: FFA1087_BCM Mixed Dyslipidemia


title: FFA1086_BCM Mixed Dyslipidemia


title: FFA1096_BCM Mixed Dyslipidemia


title: FFA1088_BCM Mixed Dyslipidemia


title: FFA1084_BCM Mixed Dyslipidemia


title: FFA1085_BCM Mixed Dyslipidemia


title: FFA1093_BCM Mixed Dyslipidemia


title: FFA1077_BCM Mixed Dyslipidemia


title: FFA1083_BCM Mixed Dyslipidemia


title: FFA1079_BCM Mixed Dyslipidemia


title: FFA1078_BCM Mixed Dyslipidemia


title: FFA1081_BCM Mixed Dyslipidemia


title: FFA1082_BCM Mixed Dyslipidemia


title: FFA1089_BCM Mixed Dyslipidemia


title: FFA1074_BCM Mixed Dyslipidemia


title: FFA1080_BCM Mixed Dyslipidemia


title: FFA1075_BCM Mixed Dyslipidemia


title: FFA1072_BCM Mixed Dyslipidemia


title: FFA1076_BCM Mixed Dyslipidemia


title: FFA1091_BCM Mixed Dyslipidemia


title: FFA1070_BCM Mixed Dyslipidemia


title: FFA1071_BCM Mixed Dyslipidemia


title: FFA1067_BCM Mixed Dyslipidemia


title: FFA1068_BCM Mixed Dyslipidemia


title: FFA1069_BCM Mixed Dyslipidemia


title: FFA1066_BCM Mixed Dyslipidemia


title: FFA1065_BCM Mixed Dyslipidemia


title: FFA1061_BCM Mixed Dyslipidemia


title: FFA1060_BCM Mixed Dyslipidemia


title: FFA1062_BCM Mixed Dyslipidemia


title: FFA1063_BCM Mixed Dyslipidemia


title: FFA1064_BCM Mixed Dyslipidemia


title: FFA1073_BCM Mixed Dyslipidemia


title: FFA1057_BCM Mixed Dyslipidemia


title: FFA1058_BCM Mixed Dyslipidemia


title: FFA1054_BCM Mixed Dyslipidemia


title: FFA1052_BCM Mixed Dyslipidemia


title: FFA1055_BCM Mixed Dyslipidemia


title: FFA1051_BCM Mixed Dyslipidemia


title: FFA1049_BCM Mixed Dyslipidemia


title: FFA1046_BCM Mixed Dyslipidemia


title: FFA1044_BCM Mixed Dyslipidemia


title: FFA1050_BCM Mixed Dyslipidemia


title: FFA1043_BCM Mixed Dyslipidemia


title: FFA1056_BCM Mixed Dyslipidemia


title: FFA1045_BCM Mixed Dyslipidemia


title: FFA1042_BCM Mixed Dyslipidemia


title: FFA1038_BCM Mixed Dyslipidemia


title: FFA1040_BCM Mixed Dyslipidemia


title: FFA1036_BCM Mixed Dyslipidemia


title: FFA1035_BCM Mixed Dyslipidemia


title: FFA1033_BCM Mixed Dyslipidemia


title: FFA1037_BCM Mixed Dyslipidemia


title: FFA1032_BCM Mixed Dyslipidemia


title: FFA1026_BCM Mixed Dyslipidemia


title: FFA1027_BCM Mixed Dyslipidemia


title: FFA1024_BCM Mixed Dyslipidemia


title: FFA1025_BCM Mixed Dyslipidemia


title: FFA1031_BCM Mixed Dyslipidemia


title: FFA1047_BCM Mixed Dyslipidemia


title: FFA1030_BCM Mixed Dyslipidemia


title: FFA1029_BCM Mixed Dyslipidemia


title: FFA1022_BCM Mixed Dyslipidemia


title: FFA1021_BCM Mixed Dyslipidemia


title: FFA1023_BCM Mixed Dyslipidemia


title: FFA1017_BCM Mixed Dyslipidemia


title: FFA1015_BCM Mixed Dyslipidemia


title: FFA1012_BCM Mixed Dyslipidemia


title: FFA1016_BCM Mixed Dyslipidemia


title: FFA1019_BCM Mixed Dyslipidemia


title: FFA1013_BCM Mixed Dyslipidemia


title: FFA1009_BCM Mixed Dyslipidemia


title: FFA1010_BCM Mixed Dyslipidemia


title: FFA1004_BCM Mixed Dyslipidemia


title: FFA1006_BCM Mixed Dyslipidemia


title: FFA1002_BCM Mixed Dyslipidemia


title: FFA1011_BCM Mixed Dyslipidemia


title: FFA1001_BCM Mixed Dyslipidemia


title: FFA1020_BCM Mixed Dyslipidemia


title: FFA1000_BCM Mixed Dyslipidemia


title: FFA0993_BCM Mixed Dyslipidemia


title: FFA0995_BCM Mixed Dyslipidemia


title: FFA1014_BCM Mixed Dyslipidemia


title: FFA0997_BCM Mixed Dyslipidemia


title: FFA0998_BCM Mixed Dyslipidemia


title: FFA0994_BCM Mixed Dyslipidemia


title: FFA1007_BCM Mixed Dyslipidemia


title: FFA0989_BCM Mixed Dyslipidemia


title: FFA0992_BCM Mixed Dyslipidemia


title: FFA1003_BCM Mixed Dyslipidemia


title: FFA0987_BCM Mixed Dyslipidemia


title: FFA0988_BCM Mixed Dyslipidemia


title: FFA0986_BCM Mixed Dyslipidemia


title: FFA1129_BCM Mixed Dyslipidemia


title: FFA1130_BCM Mixed Dyslipidemia


title: FFA0983_BCM Mixed Dyslipidemia


title: FFA0991_BCM Mixed Dyslipidemia


title: FFA0990_BCM Mixed Dyslipidemia


title: FFA0982_BCM Mixed Dyslipidemia


title: FFA0977_BCM Mixed Dyslipidemia


title: FFA0978_BCM Mixed Dyslipidemia


title: FFA0976_BCM Mixed Dyslipidemia


title: FFA0979_BCM Mixed Dyslipidemia


title: FFA0999_BCM Mixed Dyslipidemia


title: FFA0980_BCM Mixed Dyslipidemia


title: FFA0996_BCM Mixed Dyslipidemia


title: FFA0975_BCM Mixed Dyslipidemia


title: FFA0974_BCM Mixed Dyslipidemia


title: FFA0973_BCM Mixed Dyslipidemia


title: FFA0972_BCM Mixed Dyslipidemia


title: FFA0969_BCM Mixed Dyslipidemia


title: FFA0968_BCM Mixed Dyslipidemia


title: FFA0970_BCM Mixed Dyslipidemia


title: FFA0967_BCM Mixed Dyslipidemia


title: FFA0964_BCM Mixed Dyslipidemia


title: FFA0965_BCM Mixed Dyslipidemia


title: FFA0966_BCM Mixed Dyslipidemia


title: FFA0960_BCM Mixed Dyslipidemia


title: FFA0957_BCM Mixed Dyslipidemia


title: FFA0956_BCM Mixed Dyslipidemia


title: FFA0955_BCM Mixed Dyslipidemia


title: FFA0952_BCM Mixed Dyslipidemia


title: FFA0953_BCM Mixed Dyslipidemia


title: FFA0954_BCM Mixed Dyslipidemia


title: FFA0950_BCM Mixed Dyslipidemia


title: FFA0951_BCM Mixed Dyslipidemia


title: FFA0948_BCM Mixed Dyslipidemia


title: FFA0947_BCM Mixed Dyslipidemia


title: FFA0943_BCM Mixed Dyslipidemia


title: FFA0942_BCM Mixed Dyslipidemia


title: FFA0944_BCM Mixed Dyslipidemia


title: FFA0946_BCM Mixed Dyslipidemia


title: FFA0941_BCM Mixed Dyslipidemia


title: FFA0940_BCM Mixed Dyslipidemia


title: FFA0936_BCM Mixed Dyslipidemia


title: FFA0961_BCM Mixed Dyslipidemia


title: FFA0935_BCM Mixed Dyslipidemia


title: FFA0934_BCM Mixed Dyslipidemia


title: FFA0933_BCM Mixed Dyslipidemia


title: FFA0932_BCM Mixed Dyslipidemia


title: FFA0931_BCM Mixed Dyslipidemia


title: FFA0937_BCM Mixed Dyslipidemia


title: FFA0929_BCM Mixed Dyslipidemia


title: FFA0928_BCM Mixed Dyslipidemia


title: FFA0949_BCM Mixed Dyslipidemia


title: FFA0927_BCM Mixed Dyslipidemia


title: FFA0926_BCM Mixed Dyslipidemia


title: FFA0945_BCM Mixed Dyslipidemia


title: FFA0925_BCM Mixed Dyslipidemia


title: FFA0930_BCM Mixed Dyslipidemia


title: FFA0924_BCM Mixed Dyslipidemia


title: FFA0923_BCM Mixed Dyslipidemia


title: FFA0919_BCM Mixed Dyslipidemia


title: FFA0918_BCM Mixed Dyslipidemia


title: FFA0916_BCM Mixed Dyslipidemia


title: FFA0915_BCM Mixed Dyslipidemia


title: FFA0917_BCM Mixed Dyslipidemia


title: FFA0938_BCM Mixed Dyslipidemia


title: FFA0920_BCM Mixed Dyslipidemia


title: FFA0914_BCM Mixed Dyslipidemia


title: FFA0909_BCM Mixed Dyslipidemia


title: FFA0907_BCM Mixed Dyslipidemia


title: FFA0913_BCM Mixed Dyslipidemia


title: FFA0911_BCM Mixed Dyslipidemia


title: FFA0908_BCM Mixed Dyslipidemia


title: FFA0905_BCM Mixed Dyslipidemia


title: FFA0922_BCM Mixed Dyslipidemia


title: FFA0904_BCM Mixed Dyslipidemia


title: FFA0903_BCM Mixed Dyslipidemia


title: FFA0906_BCM Mixed Dyslipidemia


title: FFA0921_BCM Mixed Dyslipidemia


title: FFA0912_BCM Mixed Dyslipidemia


title: FFA0902_BCM Mixed Dyslipidemia


title: FFA0899_BCM Mixed Dyslipidemia


title: FFA0900_BCM Mixed Dyslipidemia


title: FFA0901_BCM Mixed Dyslipidemia


title: FFA0897_BCM Mixed Dyslipidemia


title: FFA0896_BCM Mixed Dyslipidemia


title: FFA0898_BCM Mixed Dyslipidemia


title: FFA0894_BCM Mixed Dyslipidemia


title: FFA0892_BCM Mixed Dyslipidemia


title: FFA0891_BCM Mixed Dyslipidemia


title: FFA0890_BCM Mixed Dyslipidemia


title: FFA0888_BCM Mixed Dyslipidemia


title: FFA0889_BCM Mixed Dyslipidemia


title: FFA0886_BCM Mixed Dyslipidemia


title: FFA0885_BCM Mixed Dyslipidemia


title: FFA0884_BCM Mixed Dyslipidemia


title: FFA0883_BCM Mixed Dyslipidemia


title: FFA0879_BCM Mixed Dyslipidemia


title: FFA0881_BCM Mixed Dyslipidemia


title: FFA0882_BCM Mixed Dyslipidemia


title: FFA0880_BCM Mixed Dyslipidemia


title: FFA0895_BCM Mixed Dyslipidemia


title: FFA0893_BCM Mixed Dyslipidemia


title: FFA0872_BCM Mixed Dyslipidemia


title: FFA0877_BCM Mixed Dyslipidemia


title: FFA0878_BCM Mixed Dyslipidemia


title: FFA0875_BCM Mixed Dyslipidemia


title: FFA0867_BCM Mixed Dyslipidemia


title: FFA0873_BCM Mixed Dyslipidemia


title: FFA0866_BCM Mixed Dyslipidemia


title: FFA0865_BCM Mixed Dyslipidemia


title: FFA0864_BCM Mixed Dyslipidemia


title: FFA0876_BCM Mixed Dyslipidemia


title: FFA0869_BCM Mixed Dyslipidemia


title: FFA0862_BCM Mixed Dyslipidemia


title: FFA0863_BCM Mixed Dyslipidemia


title: FFA0861_BCM Mixed Dyslipidemia


title: FFA0858_BCM Mixed Dyslipidemia


title: FFA0859_BCM Mixed Dyslipidemia


title: FFA0857_BCM Mixed Dyslipidemia


title: FFA0856_BCM Mixed Dyslipidemia


title: FFA0871_BCM Mixed Dyslipidemia


title: FFA0870_BCM Mixed Dyslipidemia


title: FFA0855_BCM Mixed Dyslipidemia


title: FFA0854_BCM Mixed Dyslipidemia


title: FFA0853_BCM Mixed Dyslipidemia


title: FFA0850_BCM Mixed Dyslipidemia


title: FFA0849_BCM Mixed Dyslipidemia


title: FFA0846_BCM Mixed Dyslipidemia


title: FFA0842_BCM Mixed Dyslipidemia


title: FFA0844_BCM Mixed Dyslipidemia


title: FFA0845_BCM Mixed Dyslipidemia


title: FFA0848_BCM Mixed Dyslipidemia


title: FFA0838_BCM Mixed Dyslipidemia


title: FFA0843_BCM Mixed Dyslipidemia


title: FFA0860_BCM Mixed Dyslipidemia


title: FFA0836_BCM Mixed Dyslipidemia


title: FFA0841_BCM Mixed Dyslipidemia


title: FFA0839_BCM Mixed Dyslipidemia


title: FFA0837_BCM Mixed Dyslipidemia


title: FFA0852_BCM Mixed Dyslipidemia


title: FFA0835_BCM Mixed Dyslipidemia


title: FFA0833_BCM Mixed Dyslipidemia


title: FFA0834_BCM Mixed Dyslipidemia


title: FFA0831_BCM Mixed Dyslipidemia


title: FFA0830_BCM Mixed Dyslipidemia


title: FFA0840_BCM Mixed Dyslipidemia


title: FFA0829_BCM Mixed Dyslipidemia


title: FFA0832_BCM Mixed Dyslipidemia


title: FFA0828_BCM Mixed Dyslipidemia


title: FFA0985_BCM Mixed Dyslipidemia


title: FFA0825_BCM Mixed Dyslipidemia


title: FFA0827_BCM Mixed Dyslipidemia


title: FFA0824_BCM Mixed Dyslipidemia


title: FFA0823_BCM Mixed Dyslipidemia


title: FFA0822_BCM Mixed Dyslipidemia


title: FFA0821_BCM Mixed Dyslipidemia


title: FFA0817_BCM Mixed Dyslipidemia


title: FFA0818_BCM Mixed Dyslipidemia


title: FFA0826_BCM Mixed Dyslipidemia


title: FFA0816_BCM Mixed Dyslipidemia


title: FFA0819_BCM Mixed Dyslipidemia


title: FFA0820_BCM Mixed Dyslipidemia


title: FFA0814_BCM Mixed Dyslipidemia


title: FFA0813_BCM Mixed Dyslipidemia


title: FFA0808_BCM Mixed Dyslipidemia


title: FFA0807_BCM Mixed Dyslipidemia


title: FFA0811_BCM Mixed Dyslipidemia


title: FFA0809_BCM Mixed Dyslipidemia


title: FFA0812_BCM Mixed Dyslipidemia


title: FFA0806_BCM Mixed Dyslipidemia


title: FFA0803_BCM Mixed Dyslipidemia


title: FFA0804_BCM Mixed Dyslipidemia


title: FFA0805_BCM Mixed Dyslipidemia


title: FFA0802_BCM Mixed Dyslipidemia


title: FFA0800_BCM Mixed Dyslipidemia


title: FFA0801_BCM Mixed Dyslipidemia


title: FFA0799_BCM Mixed Dyslipidemia


title: FFA0798_BCM Mixed Dyslipidemia


title: FFA0797_BCM Mixed Dyslipidemia


title: FFA0815_BCM Mixed Dyslipidemia


title: FFA0794_BCM Mixed Dyslipidemia


title: FFA0810_BCM Mixed Dyslipidemia


title: FFA0795_BCM Mixed Dyslipidemia


title: FFA0787_BCM Mixed Dyslipidemia


title: FFA0785_BCM Mixed Dyslipidemia


title: FFA0791_BCM Mixed Dyslipidemia


title: FFA0792_BCM Mixed Dyslipidemia


title: FFA0788_BCM Mixed Dyslipidemia


title: FFA0790_BCM Mixed Dyslipidemia


title: FFA0778_BCM Mixed Dyslipidemia


title: FFA0781_BCM Mixed Dyslipidemia


title: FFA0789_BCM Mixed Dyslipidemia


title: FFA0793_BCM Mixed Dyslipidemia


title: FFA0782_BCM Mixed Dyslipidemia


title: FFA0784_BCM Mixed Dyslipidemia


title: FFA0777_BCM Mixed Dyslipidemia


title: FFA0780_BCM Mixed Dyslipidemia


title: FFA0767_BCM Mixed Dyslipidemia


title: FFA0773_BCM Mixed Dyslipidemia


title: FFA0772_BCM Mixed Dyslipidemia


title: FFA0770_BCM Mixed Dyslipidemia


title: FFA0775_BCM Mixed Dyslipidemia


title: FFA0774_BCM Mixed Dyslipidemia


title: FFA0776_BCM Mixed Dyslipidemia


title: FFA0764_BCM Mixed Dyslipidemia


title: FFA0762_BCM Mixed Dyslipidemia


title: FFA0763_BCM Mixed Dyslipidemia


title: FFA0779_BCM Mixed Dyslipidemia


title: FFA0760_BCM Mixed Dyslipidemia


title: FFA0759_BCM Mixed Dyslipidemia


title: FFA0753_BCM Mixed Dyslipidemia


title: FFA0766_BCM Mixed Dyslipidemia


title: FFA0755_BCM Mixed Dyslipidemia


title: FFA0751_BCM Mixed Dyslipidemia


title: FFA0750_BCM Mixed Dyslipidemia


title: FFA0752_BCM Mixed Dyslipidemia


title: FFA0756_BCM Mixed Dyslipidemia


title: FFA0747_BCM Mixed Dyslipidemia


title: FFA0765_BCM Mixed Dyslipidemia


title: FFA0758_BCM Mixed Dyslipidemia


title: FFA0746_BCM Mixed Dyslipidemia


title: FFA0748_BCM Mixed Dyslipidemia


title: FFA0740_BCM Mixed Dyslipidemia


title: FFA0744_BCM Mixed Dyslipidemia


title: FFA0742_BCM Mixed Dyslipidemia


title: FFA0745_BCM Mixed Dyslipidemia


title: FFA0739_BCM Mixed Dyslipidemia


title: FFA0743_BCM Mixed Dyslipidemia


title: FFA0736_BCM Mixed Dyslipidemia


title: FFA0761_BCM Mixed Dyslipidemia


title: FFA0738_BCM Mixed Dyslipidemia


title: FFA0735_BCM Mixed Dyslipidemia


title: FFA0757_BCM Mixed Dyslipidemia


title: FFA0749_BCM Mixed Dyslipidemia


title: FFA0732_BCM Mixed Dyslipidemia


title: FFA0741_BCM Mixed Dyslipidemia


title: FFA0737_BCM Mixed Dyslipidemia


title: FFA0731_BCM Mixed Dyslipidemia


title: FFA0733_BCM Mixed Dyslipidemia


title: FFA0726_BCM Mixed Dyslipidemia


title: FFA0729_BCM Mixed Dyslipidemia


title: FFA0728_BCM Mixed Dyslipidemia


title: FFA0730_BCM Mixed Dyslipidemia


title: FFA0723_BCM Mixed Dyslipidemia


title: FFA0718_BCM Mixed Dyslipidemia


title: FFA0722_BCM Mixed Dyslipidemia


title: FFA0724_BCM Mixed Dyslipidemia


title: FFA0720_BCM Mixed Dyslipidemia


title: FFA0725_BCM Mixed Dyslipidemia


title: FFA0719_BCM Mixed Dyslipidemia


title: FFA0734_BCM Mixed Dyslipidemia


title: FFA0721_BCM Mixed Dyslipidemia


title: FFA0727_BCM Mixed Dyslipidemia


title: FFA0713_BCM Mixed Dyslipidemia


title: FFA0716_BCM Mixed Dyslipidemia


title: FFA0715_BCM Mixed Dyslipidemia


title: FFA0711_BCM Mixed Dyslipidemia


title: FFA0712_BCM Mixed Dyslipidemia


title: FFA0717_BCM Mixed Dyslipidemia


title: FFA0708_BCM Mixed Dyslipidemia

value: fenofibric acid+statin


title: FFA0709_BCM Mixed Dyslipidemia


title: FFA0707_BCM Mixed Dyslipidemia


title: FFA0706_BCM Mixed Dyslipidemia


title: FFA0703_BCM Mixed Dyslipidemia


title: FFA0705_BCM Mixed Dyslipidemia


title: FFA0701_BCM Mixed Dyslipidemia


title: FFA0702_BCM Mixed Dyslipidemia


title: FFA0714_BCM Mixed Dyslipidemia


title: FFA0698_BCM Mixed Dyslipidemia


title: FFA0699_BCM Mixed Dyslipidemia


title: FFA0695_BCM Mixed Dyslipidemia


title: FFA0692_BCM Mixed Dyslipidemia


title: FFA0696_BCM Mixed Dyslipidemia


title: FFA0700_BCM Mixed Dyslipidemia


title: FFA0694_BCM Mixed Dyslipidemia


title: FFA0690_BCM Mixed Dyslipidemia


title: FFA0697_BCM Mixed Dyslipidemia


title: FFA0686_BCM Mixed Dyslipidemia


title: FFA0683_BCM Mixed Dyslipidemia


title: FFA0681_BCM Mixed Dyslipidemia


title: FFA0689_BCM Mixed Dyslipidemia


title: FFA0691_BCM Mixed Dyslipidemia


title: FFA0685_BCM Mixed Dyslipidemia


title: FFA0682_BCM Mixed Dyslipidemia


title: FFA0688_BCM Mixed Dyslipidemia


title: FFA0679_BCM Mixed Dyslipidemia


title: FFA0676_BCM Mixed Dyslipidemia


title: FFA0677_BCM Mixed Dyslipidemia


title: FFA0675_BCM Mixed Dyslipidemia


title: FFA0678_BCM Mixed Dyslipidemia


title: FFA0673_BCM Mixed Dyslipidemia


title: FFA0674_BCM Mixed Dyslipidemia


title: FFA0671_BCM Mixed Dyslipidemia


title: FFA0672_BCM Mixed Dyslipidemia


title: FFA0693_BCM Mixed Dyslipidemia


title: FFA0670_BCM Mixed Dyslipidemia


title: FFA0680_BCM Mixed Dyslipidemia


title: FFA0710_BCM Mixed Dyslipidemia


title: FFA0666_BCM Mixed Dyslipidemia


title: FFA0665_BCM Mixed Dyslipidemia


title: FFA0663_BCM Mixed Dyslipidemia


title: FFA0668_BCM Mixed Dyslipidemia


title: FFA0661_BCM Mixed Dyslipidemia


title: FFA0667_BCM Mixed Dyslipidemia


title: FFA0659_BCM Mixed Dyslipidemia


title: FFA0657_BCM Mixed Dyslipidemia


title: FFA0664_BCM Mixed Dyslipidemia


title: FFA0656_BCM Mixed Dyslipidemia


title: FFA0653_BCM Mixed Dyslipidemia


title: FFA0652_BCM Mixed Dyslipidemia


title: FFA0651_BCM Mixed Dyslipidemia


title: FFA0647_BCM Mixed Dyslipidemia


title: FFA0645_BCM Mixed Dyslipidemia


title: FFA0646_BCM Mixed Dyslipidemia


title: FFA0650_BCM Mixed Dyslipidemia


title: FFA0649_BCM Mixed Dyslipidemia


title: FFA0644_BCM Mixed Dyslipidemia


title: FFA0648_BCM Mixed Dyslipidemia


title: FFA0669_BCM Mixed Dyslipidemia


title: FFA0639_BCM Mixed Dyslipidemia


title: FFA0643_BCM Mixed Dyslipidemia


title: FFA0662_BCM Mixed Dyslipidemia


title: FFA0641_BCM Mixed Dyslipidemia


title: FFA0658_BCM Mixed Dyslipidemia


title: FFA0638_BCM Mixed Dyslipidemia


title: FFA0655_BCM Mixed Dyslipidemia


title: FFA0654_BCM Mixed Dyslipidemia


title: FFA0637_BCM Mixed Dyslipidemia


title: FFA0636_BCM Mixed Dyslipidemia


title: FFA0629_BCM Mixed Dyslipidemia


title: FFA0634_BCM Mixed Dyslipidemia


title: FFA0631_BCM Mixed Dyslipidemia


title: FFA0632_BCM Mixed Dyslipidemia


title: FFA0635_BCM Mixed Dyslipidemia


title: FFA0630_BCM Mixed Dyslipidemia


title: FFA0633_BCM Mixed Dyslipidemia


title: FFA0624_BCM Mixed Dyslipidemia


title: FFA0626_BCM Mixed Dyslipidemia


title: FFA0627_BCM Mixed Dyslipidemia


title: FFA0623_BCM Mixed Dyslipidemia


title: FFA0628_BCM Mixed Dyslipidemia


title: FFA0625_BCM Mixed Dyslipidemia


title: FFA0615_BCM Mixed Dyslipidemia


title: FFA0620_BCM Mixed Dyslipidemia


title: FFA0616_BCM Mixed Dyslipidemia


title: FFA0617_BCM Mixed Dyslipidemia


title: FFA0621_BCM Mixed Dyslipidemia


title: FFA0619_BCM Mixed Dyslipidemia


title: FFA0611_BCM Mixed Dyslipidemia


title: FFA0613_BCM Mixed Dyslipidemia


title: FFA0612_BCM Mixed Dyslipidemia


title: FFA0614_BCM Mixed Dyslipidemia


title: FFA0618_BCM Mixed Dyslipidemia


title: FFA0609_BCM Mixed Dyslipidemia


title: FFA0606_BCM Mixed Dyslipidemia


title: FFA0607_BCM Mixed Dyslipidemia


title: FFA0608_BCM Mixed Dyslipidemia


title: FFA0605_BCM Mixed Dyslipidemia


title: FFA0602_BCM Mixed Dyslipidemia


title: FFA0604_BCM Mixed Dyslipidemia


title: FFA0601_BCM Mixed Dyslipidemia


title: FFA0600_BCM Mixed Dyslipidemia


title: FFA0603_BCM Mixed Dyslipidemia


title: FFA0599_BCM Mixed Dyslipidemia


title: FFA0597_BCM Mixed Dyslipidemia


title: FFA0592_BCM Mixed Dyslipidemia


title: FFA0593_BCM Mixed Dyslipidemia


title: FFA0594_BCM Mixed Dyslipidemia


title: FFA0591_BCM Mixed Dyslipidemia


title: FFA0588_BCM Mixed Dyslipidemia


title: FFA0586_BCM Mixed Dyslipidemia


title: FFA0587_BCM Mixed Dyslipidemia


title: FFA0585_BCM Mixed Dyslipidemia


title: FFA0589_BCM Mixed Dyslipidemia


title: FFA0590_BCM Mixed Dyslipidemia


title: FFA0584_BCM Mixed Dyslipidemia


title: FFA0583_BCM Mixed Dyslipidemia


title: FFA0581_BCM Mixed Dyslipidemia


title: FFA0580_BCM Mixed Dyslipidemia


title: FFA0582_BCM Mixed Dyslipidemia


title: FFA0578_BCM Mixed Dyslipidemia


title: FFA0575_BCM Mixed Dyslipidemia


title: FFA0577_BCM Mixed Dyslipidemia


title: FFA0573_BCM Mixed Dyslipidemia


title: FFA0574_BCM Mixed Dyslipidemia


title: FFA0598_BCM Mixed Dyslipidemia


title: FFA0596_BCM Mixed Dyslipidemia


title: FFA0595_BCM Mixed Dyslipidemia


title: FFA0572_BCM Mixed Dyslipidemia


title: FFA0566_BCM Mixed Dyslipidemia


title: FFA0569_BCM Mixed Dyslipidemia


title: FFA0571_BCM Mixed Dyslipidemia


title: FFA0568_BCM Mixed Dyslipidemia


title: FFA0562_BCM Mixed Dyslipidemia


title: FFA0565_BCM Mixed Dyslipidemia


title: FFA0564_BCM Mixed Dyslipidemia


title: FFA0561_BCM Mixed Dyslipidemia


title: FFA0560_BCM Mixed Dyslipidemia


title: FFA0559_BCM Mixed Dyslipidemia


title: FFA0556_BCM Mixed Dyslipidemia


title: FFA0557_BCM Mixed Dyslipidemia


title: FFA0558_BCM Mixed Dyslipidemia


title: FFA0554_BCM Mixed Dyslipidemia


title: FFA0553_BCM Mixed Dyslipidemia


title: FFA0555_BCM Mixed Dyslipidemia


title: FFA0570_BCM Mixed Dyslipidemia


title: FFA0547_BCM Mixed Dyslipidemia


title: FFA0552_BCM Mixed Dyslipidemia


title: FFA0551_BCM Mixed Dyslipidemia


title: FFA0549_BCM Mixed Dyslipidemia


title: FFA0550_BCM Mixed Dyslipidemia


title: FFA0545_BCM Mixed Dyslipidemia


title: FFA0567_BCM Mixed Dyslipidemia


title: FFA0548_BCM Mixed Dyslipidemia


title: FFA0543_BCM Mixed Dyslipidemia


title: FFA0544_BCM Mixed Dyslipidemia


title: FFA0541_BCM Mixed Dyslipidemia


title: FFA0542_BCM Mixed Dyslipidemia


title: FFA0540_BCM Mixed Dyslipidemia


title: FFA0537_BCM Mixed Dyslipidemia


title: FFA0539_BCM Mixed Dyslipidemia


title: FFA0535_BCM Mixed Dyslipidemia


title: FFA0534_BCM Mixed Dyslipidemia


title: FFA0533_BCM Mixed Dyslipidemia


title: FFA0529_BCM Mixed Dyslipidemia


title: FFA0528_BCM Mixed Dyslipidemia


title: FFA0526_BCM Mixed Dyslipidemia


title: FFA0530_BCM Mixed Dyslipidemia


title: FFA0546_BCM Mixed Dyslipidemia


title: FFA0524_BCM Mixed Dyslipidemia


title: FFA0523_BCM Mixed Dyslipidemia


title: FFA0521_BCM Mixed Dyslipidemia


title: FFA0515_BCM Mixed Dyslipidemia


title: FFA0517_BCM Mixed Dyslipidemia


title: FFA0516_BCM Mixed Dyslipidemia


title: FFA0538_BCM Mixed Dyslipidemia


title: FFA0518_BCM Mixed Dyslipidemia


title: FFA0519_BCM Mixed Dyslipidemia


title: FFA0509_BCM Mixed Dyslipidemia


title: FFA0506_BCM Mixed Dyslipidemia


title: FFA0510_BCM Mixed Dyslipidemia


title: FFA0507_BCM Mixed Dyslipidemia


title: FFA0520_BCM Mixed Dyslipidemia


title: FFA0508_BCM Mixed Dyslipidemia


title: FFA0505_BCM Mixed Dyslipidemia


title: FFA0511_BCM Mixed Dyslipidemia


title: FFA0503_BCM Mixed Dyslipidemia


title: FFA0514_BCM Mixed Dyslipidemia


title: FFA0525_BCM Mixed Dyslipidemia


title: FFA0532_BCM Mixed Dyslipidemia


title: FFA0501_BCM Mixed Dyslipidemia


title: FFA0499_BCM Mixed Dyslipidemia


title: FFA0497_BCM Mixed Dyslipidemia


title: FFA0498_BCM Mixed Dyslipidemia


title: FFA0495_BCM Mixed Dyslipidemia


title: FFA0496_BCM Mixed Dyslipidemia


title: FFA0494_BCM Mixed Dyslipidemia


title: FFA0493_BCM Mixed Dyslipidemia


title: FFA0492_BCM Mixed Dyslipidemia


title: FFA0490_BCM Mixed Dyslipidemia


title: FFA0487_BCM Mixed Dyslipidemia


title: FFA0488_BCM Mixed Dyslipidemia


title: FFA0502_BCM Mixed Dyslipidemia


title: FFA0491_BCM Mixed Dyslipidemia


title: FFA0489_BCM Mixed Dyslipidemia


title: FFA0486_BCM Mixed Dyslipidemia


title: FFA0485_BCM Mixed Dyslipidemia


title: FFA0481_BCM Mixed Dyslipidemia


title: FFA0482_BCM Mixed Dyslipidemia


title: FFA0477_BCM Mixed Dyslipidemia


title: FFA0500_BCM Mixed Dyslipidemia


title: FFA0479_BCM Mixed Dyslipidemia


title: FFA0483_BCM Mixed Dyslipidemia


title: FFA0478_BCM Mixed Dyslipidemia


title: FFA0474_BCM Mixed Dyslipidemia


title: FFA0475_BCM Mixed Dyslipidemia


title: FFA0471_BCM Mixed Dyslipidemia


title: FFA0472_BCM Mixed Dyslipidemia


title: FFA0473_BCM Mixed Dyslipidemia


title: FFA0469_BCM Mixed Dyslipidemia


title: FFA0470_BCM Mixed Dyslipidemia


title: FFA0468_BCM Mixed Dyslipidemia


title: FFA0466_BCM Mixed Dyslipidemia


title: FFA0465_BCM Mixed Dyslipidemia


title: FFA0462_BCM Mixed Dyslipidemia


title: Human fetal colon EGF 4

type: RNA

city: Sherbrooke

first: Jean-François

last: Beaulieu

state: Québec

address: 3001, 12ème avenue nord

department: Anatomie & biologie cellulaire

country: Canada

institute: Université de Sherbrooke

description:
Colon EGF#4
Biological replicate 4

hyb_protocol: Standard Illumina hybridization protocol

scan_protocol: Standard Illumina scanning protocol

data_processing: The data were normalised using quantile normalisation with IlluminaGUI in R

label: biotin

molecule: total RNA

source_name: Human fetal colon

label_protocol: Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays

extract_protocol: Total RNA extracted using Trizol following manufacturer's instructions

tag: developmental stage

value: fetus

tag: age (weeks of gestation)

value: intestinal explant

tag: intestine segment

value: colon

tag: agent

value: EGF


title: Human fetal colon EGF 3

description:
Colon EGF#3
Biological replicate 3


title: FFA0463_BCM Mixed Dyslipidemia


title: Human fetal colon EGF 2

description:
Colon EGF#2
Biological replicate 2


title: Human fetal colon EGF 1

description:
Colon EGF#1
Biological replicate 1


title: Human fetal colon control 4

description:
Colon Ctrl#4
Biological replicate 4

value: control


title: Human fetal colon control 2

description:
Colon Ctrl#2
Biological replicate 2


title: FFA0460_BCM Mixed Dyslipidemia


title: Human fetal colon control 3

description:
Colon Ctrl#3
Biological replicate 3


title: FFA0458_BCM Mixed Dyslipidemia


title: FFA0459_BCM Mixed Dyslipidemia


title: FFA0457_BCM Mixed Dyslipidemia


title: FFA0467_BCM Mixed Dyslipidemia


title: FFA0455_BCM Mixed Dyslipidemia


title: FFA0452_BCM Mixed Dyslipidemia


title: FFA0454_BCM Mixed Dyslipidemia


title: FFA0453_BCM Mixed Dyslipidemia


title: FFA0461_BCM Mixed Dyslipidemia


title: FFA0451_BCM Mixed Dyslipidemia


title: FFA0447_BCM Mixed Dyslipidemia


title: FFA0445_BCM Mixed Dyslipidemia


title: Human fetal ileum EGF 2

description:
Ileum EGF#2
Biological replicate 2

source_name: Human fetal ileum

value: ileum


title: FFA0448_BCM Mixed Dyslipidemia


title: FFA0446_BCM Mixed Dyslipidemia


title: FFA0449_BCM Mixed Dyslipidemia


title: Human fetal ileum control 2

description:
Ileum Ctrl#2
Biological replicate 2


title: Human fetal ileum EGF 1

description:
Ileum EGF#1
Biological replicate 1


title: Human fetal ileum EGF 4

description:
Ileum EGF#4
Biological replicate 4


title: Human fetal colon control 1

description:
Colon Ctrl#1
Biological replicate 1


title: Human fetal ileum control 4

description:
Ileum Ctrl#4
Biological replicate 4


title: Human fetal ileum EGF 3

description:
Ileum EGF#3
Biological replicate 3


title: Human fetal ileum control 3

description:
Ileum Ctrl#3
Biological replicate 3


title: FFA0443_BCM Mixed Dyslipidemia


title: Human fetal ileum control 1

description:
Ileum Ctrl#1
Biological replicate 1


title: FFA0442_BCM Mixed Dyslipidemia


title: FFA0441_BCM Mixed Dyslipidemia


title: FFA0440_BCM Mixed Dyslipidemia


title: FFA0439_BCM Mixed Dyslipidemia


title: FFA0437_BCM Mixed Dyslipidemia


title: FFA0450_BCM Mixed Dyslipidemia


title: FFA0431_BCM Mixed Dyslipidemia


title: FFA0436_BCM Mixed Dyslipidemia


title: FFA0435_BCM Mixed Dyslipidemia


title: FFA0434_BCM Mixed Dyslipidemia


title: FFA0444_BCM Mixed Dyslipidemia


title: FFA0433_BCM Mixed Dyslipidemia


title: FFA0438_BCM Mixed Dyslipidemia


title: FFA0430_BCM Mixed Dyslipidemia


title: FFA0422_BCM Mixed Dyslipidemia


title: FFA0424_BCM Mixed Dyslipidemia


title: FFA0420_BCM Mixed Dyslipidemia


title: FFA0432_BCM Mixed Dyslipidemia


title: FFA0418_BCM Mixed Dyslipidemia


title: FFA0419_BCM Mixed Dyslipidemia


title: Dispersed oil, rep 4

city: Bangor

first: Sharon

middle: E.

last: Hook

state: NSW

address: Private Mail Bag 7

department: Centre for Environmental Contaminants Research

country: Australia

institute: CSIRO

hyb_protocol: Hybs were performed at the Ramacioti Centre following standardized protocols for Agilent two colour arrays

scan_protocol: Images were quantified using Agilent Feature Extraction Software (version A.7.5).

data_processing: LOWESS normalized, background subtracted data obtained from log2 of processed Red signal/processed Green signal. Agilent software was used.

label: Cy 3

organism: Phaeodactylum tricornutum

source_name: Dispersed oil

label_protocol: Controls (reference) were labelled with CY3

growth_protocol: 96 hour growth, 5 x 10^7 cells were harvested

extract_protocol: Cells were lysed in a guadnine thiocyanate buffer via vortexing with glass beads. TRIzol followed by Rneasy cleanup.

treatment_protocol: stressors were added to filtered sea water amended with 260 uM  NO3, 130 uM PO4

tag: treatment

value: Diatom cells were grown in the WAF of 0.1 g/L Cossack Crude Oil treated with 10 mg of Slickgone dispersant, replicate 4

label: Cy 5

source_name: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 2


title: FFA0416_BCM Mixed Dyslipidemia


title: Oil rep 1

source_name: Oil

value: Diatom cells were grown in the WAF of 5 g/L Cossack Crude Oil , replicate 1

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 2


title: Mixture rep 2

source_name: Mixture

value: Diatom cells were grown in seawater with a salinity of 10 ppt, using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, with added 35 ug/L Cadmium sulphate, replicate 2


title: FFA0415_BCM Mixed Dyslipidemia


title: FFA0429_BCM Mixed Dyslipidemia


title: FFA0427_BCM Mixed Dyslipidemia


title: FFA0426_BCM Mixed Dyslipidemia


title: FFA0414_BCM Mixed Dyslipidemia


title: FFA0413_BCM Mixed Dyslipidemia


title: FFA0409_BCM Mixed Dyslipidemia


title: FFA0407_BCM Mixed Dyslipidemia


title: FFA0412_BCM Mixed Dyslipidemia


title: FFA0410_BCM Mixed Dyslipidemia


title: Control rep 2

source_name: Control


title: Simazine rep 1

source_name: Simazine

value: Diatom cells were grown in media containing 75 ug/L simazine, replicate 1


title: FFA0411_BCM Mixed Dyslipidemia


title: Dispersant rep 3

source_name: Dispersant

value: Diatom cells were grown in media containing 25 mg/L of the dispersant slickgone NS, replicate 3


title: FFA0417_BCM Mixed Dyslipidemia


title: Copper rep 4

source_name: Copper

value: Diatom cells were grown in media containing 2 ug/L copper sulphate, replicate 4


title: Ammonia rep 2

source_name: Ammonia

value: Diatoms cells were grown using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, replicate 2


title: FFA0406_BCM Mixed Dyslipidemia

value: Mixed dyslipidemia

value: peripheral blood


title: Copper rep 2

value: Diatom cells were grown in media containing 2 ug/L copper sulphate, replicate 2


title: FFA0404_BCM Mixed Dyslipidemia

value: fenofibric acid+statin


title: FFA0405_BCM Mixed Dyslipidemia


title: FFA0403_BCM Mixed Dyslipidemia


title: FFA0402_BCM Mixed Dyslipidemia


title: FFA0401_BCM Mixed Dyslipidemia


title: Dispersant rep 2

value: Diatom cells were grown in media containing 25 mg/L of the dispersant slickgone NS, replicate 2


title: Dispersed oil, rep 3

value: Diatom cells were grown in the WAF of 0.1 g/L Cossack Crude Oil treated with 10 mg of Slickgone dispersant, replicate 3


title: FFA0400_BCM Mixed Dyslipidemia


title: FFA0396_BCM Mixed Dyslipidemia


title: FFA0395_BCM Mixed Dyslipidemia


title: FFA0391_BCM Mixed Dyslipidemia


title: FFA0398_BCM Mixed Dyslipidemia


title: FFA0390_BCM Mixed Dyslipidemia


title: FFA0397_BCM Mixed Dyslipidemia


title: FFA0392_BCM Mixed Dyslipidemia


title: FFA0399_BCM Mixed Dyslipidemia


title: FFA0394_BCM Mixed Dyslipidemia


title: FFA0385_BCM Mixed Dyslipidemia


title: FFA0386_BCM Mixed Dyslipidemia


title: Silver rep 4

source_name: Silver

value: Diatom cells were grown in media containing 35 ug/L silver nitrate, replicate 4


title: FFA0384_BCM Mixed Dyslipidemia


title: Salinity 15 ppt rep 3

source_name: Salinity 15 ppt

value: Diatom cells were grown in seawater with a salinity of 15 ppt, replicate 3


title: FFA0389_BCM Mixed Dyslipidemia


title: FFA0387_BCM Mixed Dyslipidemia


title: Salinity 15 ppt rep 5

value: Diatom cells were grown in seawater with a salinity of 15 ppt, replicate 5


title: FFA0383_BCM Mixed Dyslipidemia


title: Copper rep 3

value: Diatom cells were grown in media containing 2 ug/L copper sulphate, replicate 3


title: Control rep 3

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 3


title: FFA0382_BCM Mixed Dyslipidemia


title: FFA0380_BCM Mixed Dyslipidemia


title: Simazine rep 3

value: Diatom cells were grown in media containing 75 ug/L simazine, replicate 3

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 2


title: Cadmium rep 5

source_name: Cadmium

value: Diatom cells were grown in media containing 5 ug/L cadmium sulphate, replicate 5


title: Mixture rep 1

value: Diatom cells were grown in seawater with a salinity of 10 ppt, using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, with added 35 ug/L Cadmium sulphate, replicate 1


title: FFA0378_BCM Mixed Dyslipidemia


title: FFA0379_BCM Mixed Dyslipidemia


title: Cadmium rep 4

value: Diatom cells were grown in media containing 5 ug/L cadmium sulphate, replicate 4


title: FFA0377_BCM Mixed Dyslipidemia


title: FFA0375_BCM Mixed Dyslipidemia


title: FFA0376_BCM Mixed Dyslipidemia


title: FFA0374_BCM Mixed Dyslipidemia


title: Control rep 6

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 6


title: Dispersant rep 1

value: Diatom cells were grown in media containing 25 mg/L of the dispersant slickgone NS, replicate 1


title: FFA0373_BCM Mixed Dyslipidemia

value: Mixed dyslipidemia

value: peripheral blood


title: FFA0372_BCM Mixed Dyslipidemia

value: fenofibric acid+statin


title: FFA0371_BCM Mixed Dyslipidemia


title: FFA0369_BCM Mixed Dyslipidemia


title: Oil rep 4

value: Diatom cells were grown in the WAF of 5 g/L Cossack Crude Oil , replicate 4


title: FFA0368_BCM Mixed Dyslipidemia


title: FFA0364_BCM Mixed Dyslipidemia


title: Silver rep 1

value: Diatom cells were grown in media containing 35 ug/L silver nitrate, replicate 1


title: FFA0423_BCM Mixed Dyslipidemia


title: Silver rep 3

value: Diatom cells were grown in media containing 35 ug/L silver nitrate, replicate 3


title: FFA0362_BCM Mixed Dyslipidemia


title: Salinity 15 ppt rep 1

value: Diatom cells were grown in seawater with a salinity of 15 ppt, replicate 1


title: FFA0358_BCM Mixed Dyslipidemia


title: FFA0357_BCM Mixed Dyslipidemia


title: FFA0360_BCM Mixed Dyslipidemia


title: Control rep 1

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 1


title: FFA0356_BCM Mixed Dyslipidemia


title: Control rep 5

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 5


title: FFA0359_BCM Mixed Dyslipidemia


title: Cadmium rep 2

value: Diatom cells were grown in media containing 5 ug/L cadmium sulphate, replicate 2


title: FFA0354_BCM Mixed Dyslipidemia


title: Cadmium rep 3

value: Diatom cells were grown in media containing 5 ug/L cadmium sulphate, replicate 3


title: FFA0355_BCM Mixed Dyslipidemia


title: FFA0365_BCM Mixed Dyslipidemia


title: FFA0363_BCM Mixed Dyslipidemia


title: Oil rep 2

value: Diatom cells were grown in the WAF of 5 g/L Cossack Crude Oil , replicate 2

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 2


title: Ammonia rep 3

value: Diatoms cells were grown using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, replicate 3


title: FFA0353_BCM Mixed Dyslipidemia


title: FFA0350_BCM Mixed Dyslipidemia


title: FFA0352_BCM Mixed Dyslipidemia


title: FFA0351_BCM Mixed Dyslipidemia


title: Silver rep 5

value: Diatom cells were grown in media containing 35 ug/L silver nitrate, replicate 5


title: Simazine rep 4

value: Diatom cells were grown in media containing 75 ug/L simazine, replicate 4


title: FFA0361_BCM Mixed Dyslipidemia


title: Mixture rep 5

value: Diatom cells were grown in seawater with a salinity of 10 ppt, using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, with added 35 ug/L Cadmium sulphate, replicate 5


title: FFA0346_BCM Mixed Dyslipidemia

value: Mixed dyslipidemia


title: FFA0343_BCM Mixed Dyslipidemia

value: peripheral blood


title: FFA0344_BCM Mixed Dyslipidemia

value: fenofibric acid+statin


title: FFA0345_BCM Mixed Dyslipidemia


title: FFA0340_BCM Mixed Dyslipidemia


title: FFA0339_BCM Mixed Dyslipidemia


title: FFA0342_BCM Mixed Dyslipidemia


title: FFA0349_BCM Mixed Dyslipidemia


title: FFA0348_BCM Mixed Dyslipidemia


title: FFA0338_BCM Mixed Dyslipidemia


title: FFA0335_BCM Mixed Dyslipidemia


title: FFA0336_BCM Mixed Dyslipidemia


title: FFA0337_BCM Mixed Dyslipidemia


title: Copper rep 5

value: Diatom cells were grown in media containing 2 ug/L copper sulphate, replicate 5


title: Cadmium rep 1

value: Diatom cells were grown in media containing 5 ug/L cadmium sulphate, replicate 1


title: Mixture rep 4

value: Diatom cells were grown in seawater with a salinity of 10 ppt, using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, with added 35 ug/L Cadmium sulphate, replicate 4


title: FFA0332_BCM Mixed Dyslipidemia


title: Mixture rep 3

value: Diatom cells were grown in seawater with a salinity of 10 ppt, using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, with added 35 ug/L Cadmium sulphate, replicate 3


title: FFA0331_BCM Mixed Dyslipidemia


title: Dispersant rep 5

value: Diatom cells were grown in media containing 25 mg/L of the dispersant slickgone NS, replicate 5


title: Oil rep 3

value: Diatom cells were grown in the WAF of 5 g/L Cossack Crude Oil , replicate 3


title: Simazine rep 2

value: Diatom cells were grown in media containing 75 ug/L simazine, replicate 2


title: FFA0330_BCM Mixed Dyslipidemia


title: FFA0329_BCM Mixed Dyslipidemia


title: FFA0333_BCM Mixed Dyslipidemia


title: FFA0341_BCM Mixed Dyslipidemia


title: FFA0328_BCM Mixed Dyslipidemia


title: Dispersed oil, rep 5

value: Diatom cells were grown in the WAF of 0.1 g/L Cossack Crude Oil treated with 10 mg of Slickgone dispersant, replicate 5


title: Ammonia rep 5

value: Diatoms cells were grown using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, replicate 5


title: FFA0326_BCM Mixed Dyslipidemia


title: FFA0327_BCM Mixed Dyslipidemia


title: Oil rep 5

value: Diatom cells were grown in the WAF of 5 g/L Cossack Crude Oil , replicate 5

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 2


title: FFA0325_BCM Mixed Dyslipidemia


title: FFA0324_BCM Mixed Dyslipidemia


title: Dispersant rep 4

value: Diatom cells were grown in media containing 25 mg/L of the dispersant slickgone NS, replicate 4


title: FFA0323_BCM Mixed Dyslipidemia


title: Simazine rep 5

value: Diatom cells were grown in media containing 75 ug/L simazine, replicate 5


title: FFA0322_BCM Mixed Dyslipidemia


title: FFA0320_BCM Mixed Dyslipidemia


title: FFA0321_BCM Mixed Dyslipidemia


title: FFA0319_BCM Mixed Dyslipidemia


title: FFA0316_BCM Mixed Dyslipidemia


title: FFA0318_BCM Mixed Dyslipidemia


title: Salinity 15 ppt rep 2

value: Diatom cells were grown in seawater with a salinity of 15 ppt, replicate 2


title: Control rep 4

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 4


title: FFA0317_BCM Mixed Dyslipidemia

value: Mixed dyslipidemia

value: peripheral blood


title: FFA0313_BCM Mixed Dyslipidemia

value: fenofibric acid+statin


title: FFA0312_BCM Mixed Dyslipidemia


title: FFA0315_BCM Mixed Dyslipidemia


title: Dispersed oil, rep 1

value: Diatom cells were grown in the WAF of 0.1 g/L Cossack Crude Oil treated with 10 mg of Slickgone dispersant, replicate 1


title: Copper rep 1

value: Diatom cells were grown in media containing 2 ug/L copper sulphate, replicate 1


title: FFA0370_BCM Mixed Dyslipidemia


title: FFA0310_BCM Mixed Dyslipidemia


title: FFA0314_BCM Mixed Dyslipidemia


title: FFA0307_BCM Mixed Dyslipidemia


title: FFA0311_BCM Mixed Dyslipidemia


title: FFA0308_BCM Mixed Dyslipidemia


title: Ammonia rep 1

value: Diatoms cells were grown using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, replicate 1


title: Ammonia rep 4

value: Diatoms cells were grown using 260 uM ammonium sulphate as a nitrogen source instead of sodium nitrate, replicate 4


title: Silver rep 2

value: Diatom cells were grown in media containing 35 ug/L silver nitrate, replicate 2


title: FFA0306_BCM Mixed Dyslipidemia


title: FFA0305_BCM Mixed Dyslipidemia


title: FFA0304_BCM Mixed Dyslipidemia


title: Dispersed oil, rep 2

value: Diatom cells were grown in the WAF of 0.1 g/L Cossack Crude Oil treated with 10 mg of Slickgone dispersant, replicate 2


title: FFA0303_BCM Mixed Dyslipidemia


title: FFA0302_BCM Mixed Dyslipidemia


title: FFA0300_BCM Mixed Dyslipidemia


title: Blood MMP060

type: other

city: Bochum

first: Daniel

middle: Gilbert

last: Weber

address: Bürkle-de-la-Camp Platz 1

department: Molekulare Medizin

country: Germany

institute: IPA

hyb_protocol: Hybridization was performed using the microarray hybridization station HS 400 Pro (Tecan, Männedorf, Switzerland) according to Liu et al. (2008) MicroRNA expression profiling using microarrays. Nat Protoc 3: 563-578.

scan_protocol: Microarrays scanning at 635 nm for Cy5 and signal definitions were performed according to Weber et al. (2008) Oligonucleotide microarrays for the detection and identification of viable beer spoilage bacteria. J Appl Microbiol 105: 951-962.

data_processing:
Generated data were analyzed using GeneSpring GX 11.0 (Agilent Technologies). Data transformation measurements less than 0.01 were set to 0.01 and normalization per microarray was performed using the 50th percentile.
Only human microRNAs were analyzed during the study

molecule: other

source_name: Cellular fraction of peripheral human blood

label_protocol: Labeling of microRNA was performed using 5´-phosphate-cytidyl-cytidyl-Cy5-3´ (Eurogentec) according to the miRNA Microarray System Protocol (Agilent Technologies).

extract_protocol: MicroRNA isolation of blood cells seperated from plasma by centrifugation was perfomed using the RiboPure-Blood Kit (Applied Biosystems) according to the alternate protocol: Isolation of Small RNAs.

tag: sample

value: Malignant mesothelioma patient

tag: age

tag: gender

value: Male

tag: smoking

value: not available

tag: histological subtype

value: Epithelioid


title: FFA0301_BCM Mixed Dyslipidemia


title: FFA0299_BCM Mixed Dyslipidemia


title: FFA0309_BCM Mixed Dyslipidemia


title: Blood MMP045

value: Ex

value: Biphasic


title: FFA0298_BCM Mixed Dyslipidemia


title: Blood MMP044


title: Salinity 15 ppt rep 4

value: Diatom cells were grown in seawater with a salinity of 10 ppt, replicate 4

value: Diatom cells harvested from seawater with added nutrients but no stressors, replicate 2


title: FFA0295_BCM Mixed Dyslipidemia

value: Mixed dyslipidemia


title: Blood MMP042

value: No

value: Sarcomatoid


title: FFA0294_BCM Mixed Dyslipidemia

value: peripheral blood

value: fenofibric acid+statin


title: Blood MMP057


title: FFA0291_BCM Mixed Dyslipidemia


title: Blood MMP056


title: FFA0290_BCM Mixed Dyslipidemia


title: Blood MMP040


title: FFA0286_BCM Mixed Dyslipidemia


title: FFA0289_BCM Mixed Dyslipidemia


title: Blood MMP039

value: Female


title: FFA0285_BCM Mixed Dyslipidemia


title: FFA0284_BCM Mixed Dyslipidemia


title: FFA0297_BCM Mixed Dyslipidemia


title: Blood MMP029


title: FFA0283_BCM Mixed Dyslipidemia


title: FFA0293_BCM Mixed Dyslipidemia


title: FFA0296_BCM Mixed Dyslipidemia


title: Blood MMP028


title: Blood MMP041


title: FFA0277_BCM Mixed Dyslipidemia


title: Blood MMP027


title: FFA0281_BCM Mixed Dyslipidemia


title: Blood MMP014


title: Blood MMP026


title: FFA0273_BCM Mixed Dyslipidemia


title: FFA0276_BCM Mixed Dyslipidemia


title: FFA0292_BCM Mixed Dyslipidemia


title: FFA0274_BCM Mixed Dyslipidemia


title: Blood MMP013


title: FFA0272_BCM Mixed Dyslipidemia


title: FFA0271_BCM Mixed Dyslipidemia


title: FFA0282_BCM Mixed Dyslipidemia


title: FFA0270_BCM Mixed Dyslipidemia


title: FFA0269_BCM Mixed Dyslipidemia


title: FFA0278_BCM Mixed Dyslipidemia


title: FFA0265_BCM Mixed Dyslipidemia


title: Blood MMP005


title: Blood MMP012


title: FFA0267_BCM Mixed Dyslipidemia


title: Blood MMP011


title: FFA0266_BCM Mixed Dyslipidemia


title: Blood MMP004


title: FFA0275_BCM Mixed Dyslipidemia


title: FFA0264_BCM Mixed Dyslipidemia


title: FFA0263_BCM Mixed Dyslipidemia


title: FFA0262_BCM Mixed Dyslipidemia


title: FFA0261_BCM Mixed Dyslipidemia


title: Blood MMP003


title: FFA0259_BCM Mixed Dyslipidemia


title: Blood MMP002


title: FFA0258_BCM Mixed Dyslipidemia


title: Blood MMP001


title: FFA0256_BCM Mixed Dyslipidemia


title: FFA0257_BCM Mixed Dyslipidemia


title: FFA0255_BCM Mixed Dyslipidemia


title: Blood AEC022

value: Asbestos-exposed control

value: Yes


title: Blood MMP000


title: FFA0254_BCM Mixed Dyslipidemia


title: FFA0251_BCM Mixed Dyslipidemia


title: Blood AEC021


title: FFA0249_BCM Mixed Dyslipidemia


title: FFA0247_BCM Mixed Dyslipidemia


title: FFA0248_BCM Mixed Dyslipidemia


title: Blood AEC020


title: FFA0244_BCM Mixed Dyslipidemia


title: Blood AEC019


title: Blood AEC018


title: FFA0240_BCM Mixed Dyslipidemia


title: FFA0242_BCM Mixed Dyslipidemia


title: FFA0239_BCM Mixed Dyslipidemia


title: Blood AEC017


title: FFA0237_BCM Mixed Dyslipidemia

source_name: Mixed dyslipidemia_fenofibric acid

value: fenofibric acid


title: FFA0252_BCM Mixed Dyslipidemia


title: FFA0236_BCM Mixed Dyslipidemia


title: FFA0245_BCM Mixed Dyslipidemia


title: Blood AEC015


title: FFA0234_BCM Mixed Dyslipidemia


title: Blood AEC016


title: Blood AEC014


title: FFA0235_BCM Mixed Dyslipidemia


title: FFA0243_BCM Mixed Dyslipidemia


title: FFA0232_BCM Mixed Dyslipidemia


title: FFA0233_BCM Mixed Dyslipidemia


title: FFA0230_BCM Mixed Dyslipidemia


title: Blood AEC012


title: Blood AEC011


title: FFA0229_BCM Mixed Dyslipidemia


title: FFA0228_BCM Mixed Dyslipidemia


title: FFA0238_BCM Mixed Dyslipidemia


title: Blood AEC010


title: FFA0227_BCM Mixed Dyslipidemia


title: Blood AEC008


title: FFA0226_BCM Mixed Dyslipidemia


title: FFA0224_BCM Mixed Dyslipidemia


title: FFA0225_BCM Mixed Dyslipidemia


title: FFA0222_BCM Mixed Dyslipidemia


title: Blood AEC005


title: FFA0223_BCM Mixed Dyslipidemia


title: FFA0221_BCM Mixed Dyslipidemia


title: Blood AEC004


title: FFA0220_BCM Mixed Dyslipidemia


title: Blood AEC002


title: FFA0215_BCM Mixed Dyslipidemia


title: FFA0218_BCM Mixed Dyslipidemia


title: FFA0216_BCM Mixed Dyslipidemia


title: FFA0219_BCM Mixed Dyslipidemia


title: FFA0212_BCM Mixed Dyslipidemia


title: FFA0213_BCM Mixed Dyslipidemia


title: FFA0214_BCM Mixed Dyslipidemia


title: FFA0209_BCM Mixed Dyslipidemia


title: FFA0210_BCM Mixed Dyslipidemia


title: FFA0211_BCM Mixed Dyslipidemia


title: FFA0207_BCM Mixed Dyslipidemia


title: FFA0206_BCM Mixed Dyslipidemia


title: FFA0204_BCM Mixed Dyslipidemia


title: FFA0203_BCM Mixed Dyslipidemia


title: FFA0202_BCM Mixed Dyslipidemia


title: FFA0200_BCM Mixed Dyslipidemia


title: Blood AEC001


title: FFA0199_BCM Mixed Dyslipidemia


title: FoxAP31KO #2

city: Baltimore

first: Minoru

last: Ko

state: MD

address: 251 Bayview Blvd, Suite 100, 10C

department: National Institute on Aging

institute: NIH

hyb_protocol: Slides were hybridized according to manufacturers protocol (Two-Color Microarray-Based Genr Expression Analysis Protocol,  Product # G4140-90050, Version 5.0.1, August 2006)

scan_protocol: Slides were scanned with an Agilent DNA Microarray Scanner (model G2505-64120) at 100% and 10% PMT in both channels, with a scan resolution of 5um.

data_processing:
Data are extracted with Agilent Feature Extraction Software.The data were further processed with NIA ANOVA tool utilities.See http://lgsun.grc.nia.nih.gov/ANOVA for details.
The data is normalized with the following method:
(1) Take values from the columns gDyeNormSignal,rDyeNormSignal in the raw files and log-transform them using: log10(max(x,1)). These values will be referenced below as Xgi and Xri where i is array number.
(2) Take average of Xri's for the oligo among 18 arrays in the series:  AverXr = average(Xri).
(3) For each array estimate Yi = Xgi-Xri+AverXr
(4) Round Yi to 4 decimal digits. This is used as the normalized VALUE.
More detailed information with error correction can be found at http://lgsun.grc.nia.nih.gov/ANOVA/help.html#arrayjoin

organism: Mus musculus

label_protocol: Total RNA was labeled using Agilents Low RNA Input Fluorescent Linear Amplification kit, according to manufacturers instructions.

extract_protocol: RNAs were isolated by Trizol by standard protocol (Invitorogen). RNA samples were then subjected to LiCl precipitation to eliminate genomic DNA contamination.

tag: cell type

value: Footpad skin

tag: strain

value: mixed sex

tag: genetic modification

value: gene knock out

tag: individual identifier

source_name: Universal Mouse Reference 129ES Cell

extract_protocol: Total RNA was extracted from cultured cells using a Stratagene Absolutely RNA kit. DNase-treated total RNA samples from 11 cultured cell lines derived from embryo, embryo fibroblast, kidney, liver/hepatocyte, lung/alveolar macrophage, B-lymphocyte, T-lymphocyte (thymus), mammary gland, muscle myoblast, skin, and testis were pooled in equal parts. The resulting URM RNA was mixed with 129ES cell RNA (Lif+) at 2:1 ratio and 2.5ug of mixed RNA was used for labeling in each tube

value: Universale Mouse Reference


title: FFA0208_BCM Mixed Dyslipidemia

tag: disease state

tag: tissue


title: FFA0198_BCM Mixed Dyslipidemia

tag: percent change in apoc3 levels

tag: treatment group


title: FoxAP31WT #1

value: Wild Type


title: FoxAP31WT #2


title: FoxAP31KO #3


title: FoxAP31WT #3


title: FFA0197_BCM Mixed Dyslipidemia


title: FoxAP14WT #3


title: FoxAP14WT #2


title: FFA0205_BCM Mixed Dyslipidemia


title: FFA0194_BCM Mixed Dyslipidemia


title: FFA0193_BCM Mixed Dyslipidemia


title: FFA0196_BCM Mixed Dyslipidemia


title: FoxAP14KO #3


title: FFA0190_BCM Mixed Dyslipidemia


title: FoxAP14WT #1


title: FFA0191_BCM Mixed Dyslipidemia


title: FoxAP14KO #1


title: FoxAP14KO #2


title: FFA0192_BCM Mixed Dyslipidemia


title: FFA0189_BCM Mixed Dyslipidemia


title: FFA0188_BCM Mixed Dyslipidemia


title: FFA0187_BCM Mixed Dyslipidemia


title: FFA0183_BCM Mixed Dyslipidemia


title: FFA0184_BCM Mixed Dyslipidemia


title: FFA0195_BCM Mixed Dyslipidemia


title: FoxAP31KO #1


title: FFA0182_BCM Mixed Dyslipidemia


title: FFA0179_BCM Mixed Dyslipidemia


title: FFA0181_BCM Mixed Dyslipidemia


title: FFA0178_BCM Mixed Dyslipidemia


title: FoxAP10WT #3


title: FoxAP10WT #2


title: FoxAP10WT #1


title: FoxAP10KO #3


title: FoxAP10KO #1


title: FoxAP10KO #2


title: FFA0176_BCM Mixed Dyslipidemia


title: FFA0174_BCM Mixed Dyslipidemia


title: FFA0180_BCM Mixed Dyslipidemia


title: FFA0173_BCM Mixed Dyslipidemia


title: FFA0171_BCM Mixed Dyslipidemia


title: FFA0177_BCM Mixed Dyslipidemia


title: FFA0170_BCM Mixed Dyslipidemia


title: P1A5 gDNA

city: St Louis

first: Michael

middle: Sean

last: Behnke

state: MO

address: 660 S. Euclid Ave

department: Molecular Microbiology

institute: Washington University School of Medicine

hyb_protocol: A total of 5 μg of labeled DNA was hybridized to Affymetrix T. gondii GeneChips using standard Affymetrix hybridization protocols.

scan_protocol: Standard Affymetrix protocol.

data_processing: GeneSpring 7.2 RMA, Data transformation: Set measurements less than 0.01 to 0.01, Per Chip: normalize to 50th percentile, Per Gene: normalize to median

organism: Toxoplasma gondii

source_name: P1A5 gDNA

label_protocol: The BioPrime Labeling System (Invitrogen) was used to label 600 ng gDNA per reaction for 2 hr at 37°C.

growth_protocol: Parasites were grown in human foreskin fibroblast (HFF) cell monolayers sustained in Dulbecco's modified Eagle medium (DMEM) supplemented with 1% fetal bovine serum at 37°C under 5% CO2

extract_protocol: Freshly egressed parasites grown in HFF cells were harvested and genomic DNA (gDNA) was purified using the DNAeasy kit (Qiagen) with addition of a RNase cocktail (Ambion).  gDNA was sheared by nebulization (Invitrogen) for 3 min at ≈ 40 psi, precipitated, washed in 70% ethanol, and re-suspended in water.

treatment_protocol: No treatment, standard growth for tachyzoites.

tag: develpomental stage

value: tachyzoite


title: FFA0167_BCM Mixed Dyslipidemia


title: FFA0169_BCM Mixed Dyslipidemia


title: P1D7 gDNA

source_name: P1D7 gDNA


title: FFA0165_BCM Mixed Dyslipidemia


title: FFA0164_BCM Mixed Dyslipidemia


title: FFA0163_BCM Mixed Dyslipidemia


title: FFA0166_BCM Mixed Dyslipidemia


title: A9AF gDNA

source_name: A9AF gDNA


title: C285-62 gDNA


title: M12AF gDNA

source_name: M12AF gDNA


title: FFA0175_BCM Mixed Dyslipidemia


title: FFA0168_BCM Mixed Dyslipidemia


title: FFA0172_BCM Mixed Dyslipidemia


title: FFA0162_BCM Mixed Dyslipidemia


title: FFA0161_BCM Mixed Dyslipidemia


title: FFA0160_BCM Mixed Dyslipidemia


title: C285-51 gDNA


title: C285-50 gDNA


title: FFA0159_BCM Mixed Dyslipidemia


title: FFA0157_BCM Mixed Dyslipidemia


title: FFA0156_BCM Mixed Dyslipidemia


title: FFA0155_BCM Mixed Dyslipidemia


title: FFA0154_BCM Mixed Dyslipidemia


title: C285-38 gDNA


title: C285-31 gDNA


title: FFA0153_BCM Mixed Dyslipidemia


title: C285-42 gDNA


title: FFA0152_BCM Mixed Dyslipidemia


title: FFA0149_BCM Mixed Dyslipidemia


title: FFA0158_BCM Mixed Dyslipidemia


title: C295-2 gDNA

source_name: C295-2 gDNA


title: FFA0144_BCM Mixed Dyslipidemia


title: FFA0145_BCM Mixed Dyslipidemia


title: FFA0143_BCM Mixed Dyslipidemia


title: FFA0148_BCM Mixed Dyslipidemia


title: FFA0146_BCM Mixed Dyslipidemia


title: FFA0150_BCM Mixed Dyslipidemia


title: FFA0138_BCM Mixed Dyslipidemia


title: FFA0137_BCM Mixed Dyslipidemia


title: FFA0151_BCM Mixed Dyslipidemia


title: FFA0139_BCM Mixed Dyslipidemia


title: FFA0141_BCM Mixed Dyslipidemia


title: FFA0142_BCM Mixed Dyslipidemia


title: FFA0135_BCM Mixed Dyslipidemia


title: FFA0134_BCM Mixed Dyslipidemia


title: FFA0133_BCM Mixed Dyslipidemia


title: FFA0132_BCM Mixed Dyslipidemia


title: FFA0131_BCM Mixed Dyslipidemia


title: FFA0130_BCM Mixed Dyslipidemia


title: E6AF gDNA

source_name: E6AF gDNA


title: FFA0128_BCM Mixed Dyslipidemia


title: FFA0129_BCM Mixed Dyslipidemia


title: FFA0136_BCM Mixed Dyslipidemia


title: FFA0127_BCM Mixed Dyslipidemia


title: FFA0125_BCM Mixed Dyslipidemia


title: FFA0122_BCM Mixed Dyslipidemia


title: FFA0121_BCM Mixed Dyslipidemia


title: FFA0123_BCM Mixed Dyslipidemia


title: C295-3 gDNA

source_name: C295-3 gDNA


title: FFA0120_BCM Mixed Dyslipidemia


title: FFA0119_BCM Mixed Dyslipidemia


title: FFA0124_BCM Mixed Dyslipidemia


title: C285-10 gDNA


title: C295-5 gDNA

source_name: C295-5 gDNA


title: C7SF gDNA

source_name: C7SF gDNA


title: C285-13 gDNA


title: C295-27 gDNA


title: B10AF gDNA

source_name: B10AF gDNA


title: B4SF gDNA

source_name: B4SF gDNA


title: FFA0118_BCM Mixed Dyslipidemia


title: FFA0115_BCM Mixed Dyslipidemia


title: FFA0114_BCM Mixed Dyslipidemia


title: C295-31 gDNA


title: C295-29 gDNA


title: FFA0116_BCM Mixed Dyslipidemia


title: FFA0107_BCM Mixed Dyslipidemia


title: FFA0105_BCM Mixed Dyslipidemia


title: FFA0106_BCM Mixed Dyslipidemia


title: FFA0104_BCM Mixed Dyslipidemia


title: FFA0108_BCM Mixed Dyslipidemia


title: FFA0109_BCM Mixed Dyslipidemia


title: FFA0110_BCM Mixed Dyslipidemia


title: FFA0111_BCM Mixed Dyslipidemia


title: FFA0112_BCM Mixed Dyslipidemia


title: FFA0113_BCM Mixed Dyslipidemia


title: E7SF gDNA

source_name: E7SF gDNA


title: D9AF gDNA

source_name: D9AF gDNA


title: FFA0102_BCM Mixed Dyslipidemia


title: FFA0103_BCM Mixed Dyslipidemia


title: C11AF gDNA

source_name: C11AF gDNA


title: SFE8 gDNA

source_name: SFE8 gDNA


title: H7AF gDNA

source_name: H7AF gDNA


title: FFA0100_BCM Mixed Dyslipidemia

source_name: Mixed dyslipidemia_fenofibric acid


title: FFA0101_BCM Mixed Dyslipidemia


title: A6AF gDNA

source_name: A6AF gDNA


title: FFA0099_BCM Mixed Dyslipidemia


title: FFA0097_BCM Mixed Dyslipidemia


title: FFA0094_BCM Mixed Dyslipidemia


title: FFA0092_BCM Mixed Dyslipidemia


title: FFA0095_BCM Mixed Dyslipidemia


title: FFA0096_BCM Mixed Dyslipidemia


title: FFA0093_BCM Mixed Dyslipidemia


title: C285-11 gDNA


title: GT1-Fudr gDNA_a

source_name: GT1-Fudr gDNA_a


title: C285-4 gDNA

source_name: C285-4 gDNA


title: CTGara gDNA_b

source_name: CTGara gDNA_b


title: CTGara gDNA_a

source_name: CTGara gDNA_a


title: C285-1 gDNA

source_name: C285-1 gDNA


title: P1D7 Cmpd1 48hr

hyb_protocol: Standard Affymetrix protocol with 5ug labeled cRNA.

scan_protocol: Standard Affymetrix protocol

data_processing: GeneSpring 7.2 RMA, Data transformation: Set measurements less than 0.01 to 0.01, Per Chip and Per Gene: Median Polishing

source_name: P1D7 Cmpd1 48hr

label_protocol: Affymetrix One Cycle: 3μg starting RNA - Standard One Cycle protocol

growth_protocol: Grown in human foreskin fibroblasts

extract_protocol: Parasites were purified from host cells and RNA was extracted using the Qiagen RNeasy kit (b-mercaptoethanol and DNase I treatment).

treatment_protocol: No treatment, standard growth for tachyzoite samples.   For bradyzoite samples, treatment with .3μM Cmpd1 for 48hrs.

value: bradyzoite

value: Cmpd1 48hr


title: GT1-Fudr gDNA_b

source_name: GT1-Fudr gDNA_b


title: FFA0086_BCM Mixed Dyslipidemia

value: Mixed dyslipidemia


title: FFA0083_BCM Mixed Dyslipidemia


title: FFA0082_BCM Mixed Dyslipidemia


title: FFA0087_BCM Mixed Dyslipidemia


title: FFA0085_BCM Mixed Dyslipidemia


title: FFA0090_BCM Mixed Dyslipidemia


title: FFA0089_BCM Mixed Dyslipidemia


title: FFA0080_BCM Mixed Dyslipidemia


title: FFA0091_BCM Mixed Dyslipidemia


title: FFA0079_BCM Mixed Dyslipidemia


title: A9SF gDNA

source_name: A9SF gDNA


title: G2SF gDNA

source_name: G2SF gDNA


title: G2AF gDNA

source_name: G2AF gDNA


title: P1A5 Cmpd1 48hr

source_name: P1A5 Cmpd1 48hr


title: M12AF Cmpd1 48hr

source_name: M12AF Cmpd1 48hr


title: FFA0078_BCM Mixed Dyslipidemia


title: A9AF Cmpd1 48hr

source_name: A9AF Cmpd1 48hr


title: C285-62 Cmpd1 48hr


title: C285-50 Cmpd1 48hr


title: C285-42 Cmpd1 48hr


title: FFA0077_BCM Mixed Dyslipidemia


title: C285-51 Cmpd1 48hr


title: FFA0075_BCM Mixed Dyslipidemia


title: FFA0076_BCM Mixed Dyslipidemia


title: C285-31 Cmpd1 48hr


title: C285-38 Cmpd1 48hr


title: FFA0074_BCM Mixed Dyslipidemia


title: C285-13 Cmpd1 48hr


title: C295-2 Cmpd1 48hr


title: FFA0073_BCM Mixed Dyslipidemia


title: FFA0072_BCM Mixed Dyslipidemia


title: EGFR KO - ras and PD153035 - repeat 3 - mAdbID:82699

city: Bethesda

first: Stuart

last: Yuspa

address: 37 Convent Dr.

institute: NCI

description: mAdb experiment ID: 82699

hyb_protocol: NCI Oligo Microarray Hybridization Other: For pre-hybrization, apply 40 ul of pre-hybridization buffer (5X SSC, 0.1% SDS, 1% BSA) to the array and incubate at 42°C for at least 30 minutes and up to an hour. Wash off the pre-hybridization solution by rapidly plunging the slide in distilled water for 2 minutes, then transfer slide to 100% isopropanol for 2 minutes. Allow slide to air dry completely prior to use. (Can spin dry if in a rush.) (NOTE: Do not exceed 1 hour after pre-hybridization/drying before setting up hybridization.) For hybridization, combine Cy3 and Cy5 labeled targets together (~9 ul recovered for each). Add 1 ul COT-1 DNA (8-10 ug/ul) and 1 ul poly A (8-10 ug/ul). Denature target at 100°C for 1 minute, then snap cool on ice. (Final volume should be about 20 ul.) Make fresh 2X Formamide hybridization buffer (50% formamide, 10X SSC, 0.2% SDS) and warm to 42°C just before adding to samples. Add 20 ul of 2X F-hyb buffer to samples. Load 40 ul sample onto microarray. Add 20 ul of 3X SSC to wells in hyb chamber to maintain humidity. Incubate overnight (12-16 hours) at 42°C in water bath or hybridization oven. After hybridization of slides, wash slides for 2 minute in 2X SSC with 0.1% SDS (with occasional plunging), for 2 minute in 1X SSC (with occasional plunging), for 2 minutes in 0.2X SSC (with occasional plunging), and spin for 3 minutes at 650 rpm to dry. (Refer to "NCI Microarray Manual")

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.17;; 3.57 Temperature: 25.17 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

data_processing:
BRB ArrayTool Data Processing
Calculation Method: Analyzed using BRBArrayTools developed by the Biometric Research Branch, National Cancer Institute (http://linus.nci.nih.gov/BRB-ArrayTools.html ). Spots with a size of <10 µm or an intensity of <100 in both the red and green channels were eliminated, followed by removal of features that were uninformative in >50% of available arrays. Each array was normalized using a Lowess Smoother with print-tip group to provide intensity-dependent normalization.

source_name: EGFR KO - ras and PD153035

label_protocol:
Cy3 Labeling Protocol
Other: Ten µg total RNA were reverse transcribed and the cDNA coupled to Cy3 dye (Amersham Biosciences, Picataway, NJ, using the indirect labeling procedure as previously described (Hlaing, M. 2004).

extract_protocol:
Sample Extraction Protocol
Other: RNA was isolated using Trizol (Invitrogen).

treatment_protocol:
Treatment type: small molecule
Agent: PD153035
Treatment dose: 1uM
Treatment time: 2hr
Treatment temperature: 37
In-vitro treatment: Cells were cultured for 4 days and then treated with 1 µM of the EGFR tyrosine kinase inhibitor, PD153035, for 2 hours.
Treatment type: viral infection
Treatment time: 4 days
Treatment temperature: 37
In-vitro treatment: Viral infections were performed using diluted supernatant from Psi-2 producer cells. Cells were cultured for 4 days following v-rasHa transduction.

value: skin

tag: developmental stage

value: newborn

value: keratinocyte

tag: genotype/variation

source_name: Universal Mouse Reference RNA

label_protocol:
Cy5 Labeling Protocol
Other: Ten µg total RNA were reverse transcribed and the cDNA coupled to Cy5 dye (Amersham Biosciences, Picataway, NJ, using the indirect labeling procedure as previously described (Hlaing, M. 2004).

extract_protocol:
Strategene UMR RNA Extraction
Other: not available

tag: other

value: Sample Pooling Protocol:Equal quantities of DNase-treated total RNA from 11 mouse cell lines (embryo; embryo, fibroblast; kidney; liver, hepatocyte; lung, alveolar macrophage; B-lymphocyte; T-lymphocyte (thymus); mammary gland; muscle myoblast; skin; testis) were pooled together.


title: C295-29 Cmpd1 48hr

tag: treatment


title: C295-27 Cmpd1 48hr


title: FFA0071_BCM Mixed Dyslipidemia

source_name: Mixed dyslipidemia_fenofibric acid

value: peripheral blood


title: E6AF Cmpd1 48hr

source_name: E6AF Cmpd1 48hr


title: EGFR KO - ras and PD153035 - repeat 5 - mAdbID:82701

description: mAdb experiment ID: 82701

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.22;; 3.72 Temperature: 26.82 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

value: embryo; embryo, fibroblast; kidney; liver, hepatocyte; lung, alveolar macrophage; B-lymphocyte; T-lymphocyte (thymus); mammary gland; muscle myoblast; skin; testis


title: EGFR KO - ras and AG1478 - repeat 2 - mAdbID:82689

description: mAdb experiment ID: 82689

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.19;; 3.62 Temperature: 26.36 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR KO - ras and AG1478

treatment_protocol:
Treatment type: small molecule
Agent: AG1478
Treatment dose: 1uM
Treatment time: 2hr
Treatment temperature: 37
In-vitro treatment: Cells were cultured for 4 days and then treated with 1 µM of the EGFR tyrosine kinase inhibitor, AG1478, for 2 hours.
Treatment type: viral infection
Treatment time: 4 days
Treatment temperature: 37
In-vitro treatment: Viral infections were performed using diluted supernatant from Psi-2 producer cells. Cells were cultured for 4 days following v-rasHa transduction.


title: EGFR KO - ras and PD153035 - repeat 4 - rev. fluor - mAdbID:82700

description: mAdb experiment ID: 82700

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.19;; 3.54 Temperature: 26.11 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR KO - ras and PD153035 - rev. fluor.

source_name: Universal Mouse Reference RNA-rev.fluor.


title: FFA0069_BCM Mixed Dyslipidemia


title: EGFR KO - ras and AG1478 - repeat 1 - mAdbID:82688

description: mAdb experiment ID: 82688

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.2;; 3.57 Temperature: 27.12 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: C295-3 Cmpd1 48hr


title: EGFR KO - ras and AG1478 - repeat 4 - rev. fluor - mAdbID:82691

description: mAdb experiment ID: 82691

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.15;; 3.63 Temperature: 26.85 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR KO - ras and AG1478 - rev. fluor.


title: EGFR KO - ras and PD153035 - repeat 2 - mAdbID:82698

description: mAdb experiment ID: 82698

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.24;; 3.52 Temperature: 27.33 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR KO - ras and PD153035 - repeat 1 - mAdbID:82696

description: mAdb experiment ID: 82696

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.17;; 3.57 Temperature: 23.92 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR WT - ras and PD153035 - repeat 4 - rev.fluor. - mAdbID:82682

description: mAdb experiment ID: 82682

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.19;; 3.69 Temperature: 24.89 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - ras and PD153035 - rev. fluor.


title: EGFR WT - ras and PD153035 - repeat 5 - mAdbID:82684

description: mAdb experiment ID: 82684

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.18;; 3.77 Temperature: 26.75 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - ras and PD153035


title: EGFR KO - ras and AG1478 - repeat 3 - mAdbID:82693

description: mAdb experiment ID: 82693

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.18;; 3.78 Temperature: 25.08 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR KO - ras and AG1478 - repeat 5 - mAdbID:82695

description: mAdb experiment ID: 82695

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.2;; 3.61 Temperature: 26.2 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR KO - ras and AG1478 - repeat 6 - mAdbID:82686

description: mAdb experiment ID: 82686

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.19;; 3.62 Temperature: 25.56 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: C7SF Cmpd1 48hr

source_name: C7SF Cmpd1 48hr


title: FFA0067_BCM Mixed Dyslipidemia

scan_protocol: After allele-specific staining BeadChip arrays were coated with XC4/ethanol , dried for 1 hour and scanned on a BeadArray Reader (Illumina).


title: FFA0070_BCM Mixed Dyslipidemia


title: FFA0068_BCM Mixed Dyslipidemia


title: FFA0066_BCM Mixed Dyslipidemia


title: C295-5 Cmpd1 48hr


title: FFA0065_BCM Mixed Dyslipidemia


title: C285-10 Cmpd1 48hr


title: C295-31 Cmpd1 48hr


title: FFA0064_BCM Mixed Dyslipidemia


title: B10AF Cmpd1 48hr

source_name: B10AF Cmpd1 48hr


title: SFE8 Cmpd1 48hr

source_name: SFE8 Cmpd1 48hr


title: EGFR WT - ras and PD153035 - repeat 1 - mAdbID:82678

description: mAdb experiment ID: 82678

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.16;; 3.77 Temperature: 24.47 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0063_BCM Mixed Dyslipidemia


title: EGFR WT - ras and PD153035 - repeat 2 - mAdbID:82679

description: mAdb experiment ID: 82679

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.16;; 3.86 Temperature: 23.85 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR WT - ras and PD153035 - repeat 3 - mAdbID:82681

description: mAdb experiment ID: 82681

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.19;; 3.68 Temperature: 26.11 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR WT - ras and AG1478 - repeat 3 - mAdbID:82676

description: mAdb experiment ID: 82676

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.21;; 3.99 Temperature: 25.32 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - ras and AG1478


title: EGFR WT - ras and AG1478 - repeat 2 - mAdbID:81381

description: mAdb experiment ID: 81381

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.42;; 3.63 Temperature: 28.04 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR WT - ras and AG1478 - repeat 4 - rev. fluor. - mAdbID:82675

description: mAdb experiment ID: 82675

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.2;; 3.78 Temperature: 24.07 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - ras and AG1478 - rev. fluor.


title: FFA0062_BCM Mixed Dyslipidemia


title: FFA0059_BCM Mixed Dyslipidemia


title: H7AF Cmpd1 48hr

scan_protocol: Standard Affymetrix protocol

source_name: H7AF Cmpd1 48hr


title: FFA0061_BCM Mixed Dyslipidemia


title: FFA0058_BCM Mixed Dyslipidemia


title: EGFR KO - ras and Erlotinib - repeat 4 - rev.fluor - mAdbID:78092

description: mAdb experiment ID: 78092

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.51;; 3.19 Temperature: 30.08 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR KO - ras and Erlotinib -rev. fluor.

treatment_protocol:
Treatment type: small molecule
Agent: Tarceva (Erlotinib)
Treatment dose: 1uM
Treatment time: 2hr
Treatment temperature: 37
In-vitro treatment: Cells were cultured for 4 days and then treated with 1 µM of the EGFR tyrosine kinase inhibitor, Erlotinib (Tarceva), for 2 hours.
Treatment type: viral infection
Treatment time: 4 days
Treatment temperature: 37
In-vitro treatment: Viral infections were performed using diluted supernatant from Psi-2 producer cells. Cells were cultured for 4 days following v-rasHa transduction.


title: EGFR WT - ras and AG1478 - repeat 5 - mAdbID:81379

description: mAdb experiment ID: 81379

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.49;; 3.8 Temperature: 28.01 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: B4SF Cmpd1 48hr

source_name: B4SF Cmpd1 48hr


title: FFA0056_BCM Mixed Dyslipidemia


title: FFA0055_BCM Mixed Dyslipidemia


title: FFA0054_BCM Mixed Dyslipidemia


title: A6AF Cmpd1 48hr

source_name: A6AF Cmpd1 48hr


title: FFA0052_BCM Mixed Dyslipidemia

source_name: Mixed dyslipidemia_fenofibric acid


title: EGFR KO - ras - repeat 4 - rev. fluor - mAdbID:78091

description: mAdb experiment ID: 78091

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.47;; 3.19 Temperature: 29.47 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR KO - ras - rev. fluor.

treatment_protocol:
Treatment type: viral infection
Treatment time: 4 days
Treatment temperature: 37
In-vitro treatment: Viral infections were performed using diluted supernatant from Psi-2 producer cells. Cells were cultured for 4 days following v-rasHa transduction.


title: FFA0060_BCM Mixed Dyslipidemia


title: C285-1 Cmpd1 48hr


title: FFA0051_BCM Mixed Dyslipidemia


title: C285-4 Cmpd1 48hr


title: EGFR WT - ras and Erlotinib - repeat 5 - mAdbID:78090

description: mAdb experiment ID: 78090

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.45;; 3.29 Temperature: 28.71 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - ras and Erlotinib

source_name: Universal Mouse Reference RNA


title: FFA0049_BCM Mixed Dyslipidemia


title: C11AF Cmpd1 48hr

source_name: C11AF Cmpd1 48hr


title: D9AF Cmpd1 48hr

source_name: D9AF Cmpd1 48hr


title: EGFR WT - ras and Erlotinib - repeat 1 - mAdbID:76517

description: mAdb experiment ID: 76517

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.38;; 3.77 Temperature: 29.1 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: C285-11 Cmpd1 48hr


title: EGFR WT - ras and AG1478 - repeat 1 - mAdbID:81380

description: mAdb experiment ID: 81380

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.43;; 3.86 Temperature: 28.71 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR WT - ras and Erlotinib - repeat 4 - rev.fluor - mAdbID:78089

description: mAdb experiment ID: 78089

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.43;; 3.36 Temperature: 27.52 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - ras and Erlotinib - rev.fluor.

source_name: Universal Mouse Reference RNA-rev.fluor.


title: E7SF Cmpd1 48hr

source_name: E7SF Cmpd1 48hr


title: EGFR WT - ras and Erlotinib - repeat 3 - mAdbID:76516

description: mAdb experiment ID: 76516

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.41;; 3.42 Temperature: 29.78 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0048_BCM Mixed Dyslipidemia


title: A9SF Cmpd1 48hr

source_name: A9SF Cmpd1 48hr


title: EGFR KO - ras and Erlotinib - repeat 3 - mAdbID:76514

description: mAdb experiment ID: 76514

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.47;; 3.89 Temperature: 27.49 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR KO - ras and Erlotinib


title: G2SF Cmpd1 48hr

source_name: G2SF Cmpd1 48hr


title: EGFR WT - ras and Erlotinib - repeat 2 - mAdbID:76515

description: mAdb experiment ID: 76515

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.42;; 3.78 Temperature: 26.88 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: GT1-Fudr Cmpd1 48hr_c

source_name: GT1-Fudr Cmpd1 48hr_c


title: GT1-Fudr Cmpd1 48hr_b

source_name: GT1-Fudr Cmpd1 48hr_b


title: G2AF Cmpd1 48hr

source_name: G2AF Cmpd1 48hr


title: EGFR KO - ras and Erlotinib - repeat 2 - mAdbID:76513

description: mAdb experiment ID: 76513

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.4;; 3.84 Temperature: 26.42 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0047_BCM Mixed Dyslipidemia

scan_protocol: After allele-specific staining BeadChip arrays were coated with XC4/ethanol , dried for 1 hour and scanned on a BeadArray Reader (Illumina).


title: FFA0046_BCM Mixed Dyslipidemia


title: FFA0045_BCM Mixed Dyslipidemia


title: CTGara Cmpd1 48hr_b

source_name: CTGara Cmpd1 48hr_b


title: EGFR KO - ras and Erlotinib - repeat 1 - mAdbID:76512

description: mAdb experiment ID: 76512

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.47;; 3.93 Temperature: 28.01 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: CTGara Cmpd1 48hr_c

source_name: CTGara Cmpd1 48hr_c


title: FFA0044_BCM Mixed Dyslipidemia

source_name: Mixed dyslipidemia_fenofibric acid


title: FFA0043_BCM Mixed Dyslipidemia


title: GT1-Fudr Cmpd1 48hr_a

source_name: GT1-Fudr Cmpd1 48hr_a


title: FFA0041_BCM Mixed Dyslipidemia


title: FFA0042_BCM Mixed Dyslipidemia


title: EGFR KO - ras - repeat 5 - mAdbID:76511

description: mAdb experiment ID: 76511

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.49;; 3.84 Temperature: 28.34 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR KO - ras


title: CTGara Cmpd1 48hr_a

source_name: CTGara Cmpd1 48hr_a


title: FFA0040_BCM Mixed Dyslipidemia


title: EGFR KO - Mock - repeat 3 - mAdbID:74282

description: mAdb experiment ID: 74282

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.48;; 3.85 Temperature: 29.01 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR KO - Mock

source_name: Universal Mouse Reference RNA


title: P1D7


title: EGFR KO - Mock - repeat 2 - mAdbID:74280

description: mAdb experiment ID: 74280

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.51;; 3.92 Temperature: 27.21 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0039_BCM Mixed Dyslipidemia


title: EGFR KO - Mock - repeat 1 - mAdbID:74281

description: mAdb experiment ID: 74281

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.49;; 3.89 Temperature: 28.16 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: P1A5

scan_protocol: Standard Affymetrix protocol


title: FFA0037_BCM Mixed Dyslipidemia


title: EGFR KO - ras - repeat 3 - mAdbID:74012

description: mAdb experiment ID: 74012

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.57;; 3.8 Temperature: 30.08 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR KO - ras - repeat 1 - mAdbID:74010

description: mAdb experiment ID: 74010

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.56;; 3.9 Temperature: 30.42 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: A9AF


title: M12AF


title: C285-51


title: EGFR KO - ras - repeat 2 - mAdbID:74011

description: mAdb experiment ID: 74011

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.56;; 4 Temperature: 29.5 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: C285-62


title: FFA0036_BCM Mixed Dyslipidemia


title: EGFR WT - Mock and PD153035 - repeat 5 - mAdbID:73800

description: mAdb experiment ID: 73800

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.53;; 4.01 Temperature: 28.55 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - Mock and PD153035

treatment_protocol:
Treatment type: small molecule
Agent: PD153035
Treatment dose: 1uM
Treatment time: 2hr
Treatment temperature: 37
In-vitro treatment: Cells were cultured for 4 days and then treated with 1 µM of the EGFR tyrosine kinase inhibitor, PD153035, for 2 hours.


title: EGFR WT - Mock and Erlotinib - repeat 5 - mAdbID:73797

description: mAdb experiment ID: 73797

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.53;; 3.97 Temperature: 29.17 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - Mock and Erlotinib

treatment_protocol:
Treatment type: small molecule
Agent: Tarceva (Erlotinib)
Treatment dose: 1uM
Treatment time: 2hr
Treatment temperature: 37
In-vitro treatment: Cells were cultured for 4 days and then treated with 1 µM of the EGFR tyrosine kinase inhibitor, Erlotinib (Tarceva), for 2 hours.


title: FFA0034_BCM Mixed Dyslipidemia


title: EGFR WT - Mock - repeat 5 - mAdbID:73794

description: mAdb experiment ID: 73794

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.46;; 3.96 Temperature: 29.9 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR WT - Mock


title: EGFR WT - Mock and AG1478 - repeat 5 - mAdbID:73795

description: mAdb experiment ID: 73795

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.44;; 3.9 Temperature: 26.63 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - Mock and AG1478

treatment_protocol:
Treatment type: small molecule
Agent: AG1478
Treatment dose: 1uM
Treatment time: 2hr
Treatment temperature: 37
In-vitro treatment: Cells were cultured for 4 days and then treated with 1 µM of the EGFR tyrosine kinase inhibitor, AG1478, for 2 hours.


title: FFA0035_BCM Mixed Dyslipidemia


title: FFA0032_BCM Mixed Dyslipidemia


title: C285-50


title: FFA0031_BCM Mixed Dyslipidemia


title: C285-42


title: C285-38


title: FFA0030_BCM Mixed Dyslipidemia


title: FFA0033_BCM Mixed Dyslipidemia


title: FFA0029_BCM Mixed Dyslipidemia


title: E6AF


title: FFA0028_BCM Mixed Dyslipidemia


title: C295-29


title: EGFR WT - ras - repeat 3 - mAdbID:73792

description: mAdb experiment ID: 73792

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.5;; 4 Temperature: 27.49 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR WT - ras


title: C295-27


title: EGFR WT - Mock and PD153035 - repeat 4 -rev.fluor. - mAdbID:73791

description: mAdb experiment ID: 73791

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.39;; 3.65 Temperature: 30.69 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - Mock and PD153035 - rev.fluor.

source_name: Universal Mouse Reference RNA-rev.fluor.


title: C285-13


title: FFA0027_BCM Mixed Dyslipidemia


title: C285-31


title: EGFR WT - ras - repeat 4 - rev. fluor. - mAdbID:73783

description: mAdb experiment ID: 73783

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.42;; 4.01 Temperature: 26.78 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR WT - ras - rev. fluor.


title: EGFR WT - Mock - repeat 1 - rev. fluor. - mAdbID:73782

description: mAdb experiment ID: 73782

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.44;; 3.96 Temperature: 29.81 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR WT - Mock - rev. fluor.


title: EGFR WT - Mock and Erlotinib- repeat 4 -rev.fluor. - mAdbID:73789

description: mAdb experiment ID: 73789

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.43;; 3.89 Temperature: 30.26 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - Mock and Erlotinib -rev.fluor.


title: EGFR WT - Mock and PD153035 - repeat 3 - mAdbID:73780

description: mAdb experiment ID: 73780

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.42;; 3.93 Temperature: 30.08 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0025_BCM Mixed Dyslipidemia

scan_protocol: After allele-specific staining BeadChip arrays were coated with XC4/ethanol , dried for 1 hour and scanned on a BeadArray Reader (Illumina).


title: FFA0023_BCM Mixed Dyslipidemia


title: FFA0024_BCM Mixed Dyslipidemia


title: FFA0022_BCM Mixed Dyslipidemia


title: C295-31


title: EGFR WT - Mock and AG1478 - repeat 4 -rev. fluor. - mAdbID:73787

description: mAdb experiment ID: 73787

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.49;; 3.99 Temperature: 26.54 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.

source_name: EGFR wt - Mock and AG1478 - rev. fluor.


title: C295-5


title: EGFR WT - Mock and Erlotinib - repeat 3 - mAdbID:73778

description: mAdb experiment ID: 73778

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.39;; 3.95 Temperature: 29.65 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0020_BCM Mixed Dyslipidemia

source_name: Mixed dyslipidemia_fenofibric acid


title: C295-3

scan_protocol: Standard Affymetrix protocol


title: EGFR WT - Mock - repeat 3 - mAdbID:73774

description: mAdb experiment ID: 73774

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.4;; 3.71 Temperature: 29.93 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: C7SF


title: EGFR WT - ras - repeat 2 - mAdbID:73773

description: mAdb experiment ID: 73773

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.35;; 3.84 Temperature: 27.06 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: C295-2


title: EGFR WT - Mock and AG1478 - repeat 3 - mAdbID:73776

description: mAdb experiment ID: 73776

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.39;; 3.96 Temperature: 29.04 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: C285-10


title: B10AF


title: EGFR WT - Mock and PD153035 - repeat 2 - mAdbID:73772

description: mAdb experiment ID: 73772

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.4;; 3.95 Temperature: 28.28 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: SFE8


title: H7AF


title: EGFR WT - ras - repeat 1 - mAdbID:73770

description: mAdb experiment ID: 73770

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.37;; 3.93 Temperature: 26.3 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: EGFR WT - Mock and AG1478 - repeat 2 - mAdbID:73771

description: mAdb experiment ID: 73771

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.38;; 3.95 Temperature: 27.43 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0021_BCM Mixed Dyslipidemia


title: EGFR WT - Mock and Erlotinib - repeat 2 - mAdbID:72202

description: mAdb experiment ID: 72202

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.42;; 3.81 Temperature: 31.33 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: B4SF


title: EGFR WT - Mock - repeat 2 - mAdbID:72201

description: mAdb experiment ID: 72201

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.46;; 3.78 Temperature: 31.67 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0017_BCM Mixed Dyslipidemia


title: D9AF


title: FFA0018_BCM Mixed Dyslipidemia


title: FFA0014_BCM Mixed Dyslipidemia


title: EGFR WT - Mock and PD153035 - repeat 1 - mAdbID:72191

description: mAdb experiment ID: 72191

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.6;; 3.43 Temperature: 31.55 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: E7SF


title: FFA0011_BCM Mixed Dyslipidemia


title: FFA0009_BCM Mixed Dyslipidemia


title: EGFR WT - Mock - repeat 1 - mAdbID:72192

description: mAdb experiment ID: 72192

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.47;; 3.65 Temperature: 30.32 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0012_BCM Mixed Dyslipidemia


title: C11AF


title: A6AF


title: FFA0008_BCM Mixed Dyslipidemia


title: FFA0010_BCM Mixed Dyslipidemia


title: EGFR WT - Mock and AG1478 - repeat 1 - mAdbID:72186

description: mAdb experiment ID: 72186

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.55;; 3.57 Temperature: 30.48 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: C285-4


title: FFA0013_BCM Mixed Dyslipidemia


title: C285-11


title: EGFR WT - Mock and Erlotinib - repeat 1 - mAdbID:72188

description: mAdb experiment ID: 72188

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.55;; 3.51 Temperature: 31.12 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: FFA0007_BCM Mixed Dyslipidemia


title: EGFR WT - ras - repeat 5 - mAdbID:72181

description: mAdb experiment ID: 72181

scan_protocol: Creator: GenePix Pro 4.0.0.54 Scanner: GenePix 4000B [84573] ScanPower: 100;; 100 LaserPower: 3.49;; 3.86 Temperature: 29.56 Scanning Protocol Other: Slides were scanned using GenePix 4000 microarray scanner (Axon Instruments, Union City, CA) with Genepix 4.0 software.


title: C285-1


title: FFA0006_BCM Mixed Dyslipidemia

scan_protocol: After allele-specific staining BeadChip arrays were coated with XC4/ethanol , dried for 1 hour and scanned on a BeadArray Reader (Illumina).


title: G2SF